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Abstract 
Heat Shock Proteins (HSPs) are a class of ubiquitously expressed and functionally 
related proteins found in all living organisms from humans to bacteria. Their 
expression is increased in response to various cellular stressors in what is referred 
to as the heat shock response. The induction of one particular HSP, HSP60, has 
been found to be correlated with mitochondria specific cell stress. Recently 
HSP60 has been found to be secreted and expressed extracellularly, after first 
being thought to be strictly intracellular. However, the mechanisms of these 
mechanisms of translocation and secretion have not been clearly identified.  
The aim of this study was to develop a model in vitro system for HSP60 
expression in human cells so that treatments which resulted in mitochondrial 
impairment could be investigated. 
This study looked at several aspects of high glucose, hydrogen peroxide (H2O2), 
and sodium azide treatment on human HeLa cells. At low levels, each treatment 
had a hormetic effect on HeLa cell growth; however at high concentrations 
growth was significantly inhibited. Additionally, high treatment concentrations 
resulted in increased cell lysis as determined by LDH assays. Treatment with 
concentrations of 100mM glucose, 200μM H2O2, and 50μM sodium azide were 
the only treatment concentrations that did not result in significantly different 
levels of cell lysis when compared to a control sample. Mitochondrial 
dehydrogenase activity was also found to be significantly decreased at high 
treatment concentrations as determined by MTT assays. Thus, 100mM glucose, 
200μM H2O2, and 50μM sodium azide treatments were identified as optimal 
conditions for mitochondrial targeted cell stress, as each of these treatments 
impaired cell growth and inhibited mitochondrial activity while having no 
significant effect on the degree of cell lysis.  
The 100mM glucose, 200μM H2O2, and 50μM sodium azide treatments were then 
investigated for the intracellular reactive oxygen species (ROS) activity they 
induced over treatment periods of 24 hours, 3 and 7 days. After 7 days of 
treatment, the 200μM H2O2 and 50μM sodium azide treatments resulted in an 
approximate three-fold increase in ROS activity, while the 100mM glucose 
treatment resulted in almost twice as much ROS compared to a control sample.  
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Finally, the effects of 100mM glucose, 200μM H2O2, and 50μM sodium azide 
treatments on HSP60 and HSP70 expression was also examined over 3 and 7 day 
time periods.  After the 7 day treatment period, the 100mM glucose treatment had 
induced a 2.43 fold increase in HSP60 expression and a 2.75 fold increase in 
HSP70 expression, the 200μM H2O2 induced a 3.48 fold increase in HSP60 
expression and a 3.98 fold increase in HSP70 expression, and finally the 50μM 
sodium azide induced a 4.74 fold increase in HSP60 expression and a 5.08 fold 
increase in HSP70 expression. 
It can therefore be concluded that 100mM glucose, 200μM H2O2, and 50μM 
sodium azide results in the upregulation of HSP60 and HSP70 in human HeLa 
cells. Therefore this model may be used to investigate further aspects of HSP60 
induction, such as its translocation and secretion.  
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1 Literature Review and Research Aims 
This chapter presents a general overview of type 2 Diabetes Mellitus and obesity. 
A review of the current literature on the roles of heat shock protein 60 (HSP60) is 
also provided, with particular emphasis on its extracellular roles and involvement 
in the promotion of atherosclerosis. The chapter will conclude with the proposed 
hypothesis.  
 
1.1 The ‘Western Disease’ Paradigm 
The ‘Western Disease’ paradigm, or ‘diseases of affluence’, is a term sometimes 
given to selected non-communicable diseases (NCDs) and other health conditions 
which are commonly thought to be a result of increasing wealth in a society 
(Ezzatti et al., 2005). While already well-established in the ‘West’, these disorders 
are also on the rise in the developing world too, and therefore are a truly global 
problem. 36 million of the 57 million global deaths in 2008 were due to non-
communicable diseases. 29% of NCD deaths in the developing world in 2008 
were premature deaths, that being deaths before the age of 60 (World Health 
Organisation, 2011).  
Factors associated with the increase of these conditions and illnesses appear to be, 
paradoxically, things which many people would regard as improvements in their 
lives; a reduction in menial physical activity, easy accessibility to low-cost foods, 
and a longer life-span. By eliminating manual tasks, people exert less energy in 
their everyday lives. This is accompanied by a ‘Western’ diet; that being low-cost, 
readily accessible fast food, with high fat and sugar contents, resulting in huge 
excess influxes of energy. This results in an energy imbalance, as people require 
less energy but consume an excessive amount. Due to the greater human longevity 
connected with the ‘Western’ lifestyle, associated problems have a much greater 
period of time to accumulate and exert their effects (Kershaw and Flier, 2004).  
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1.2 Type 2 Diabetes Mellitus 
1.2.1 Statistics 
With 346 million people worldwide diagnosed with diabetes, it is the most 
common metabolic disease in the world, of which type 2 diabetes (T2D) accounts 
for around 90%. T2D reduces projected lifespan, quality of life and has a huge 
financial cost; the United States alone exceeds $130 billion annually on diabetes 
related health care (Peterson, 2003). In 2004, an estimated 3.4 million people died 
from consequences of high blood sugar. The World Health Organisation (WHO) 
projects that diabetes related deaths will double between 2005 and 2030. (World 
Health Organisation, 2011). In New Zealand, the number of people diagnosed 
with diabetes in 1996 was 81,000 (Ministry of Health, 2007). This figure has 
grown, and is now estimated to be approaching 200,000, with the vast majority 
T2D (Ministry of Health, 2011).  Additionally, people of Māori and Pacific 
origins have approximately 2.5 times the risk of developing T2D during their lives 
compared with New Zealand Europeans. They also develop diabetes 10 years 
earlier on average. While these figures are most marked for Māori and Pacific 
peoples, the rising prevalence of diabetes in the growing population descending 
from South Asia is also concerning (Ministry of Health, 2008). Patients with T2D 
have an increased risk of cardiovascular disease (CVD), which is responsible for 
50-80% of deaths in people with diabetes (World Health Organisation, 2011). The 
common association of T2D and CVD will be reviewed in Chapter 1.4.  
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1.2.2 Definitions of Diabetes 
The WHO’s definitions of diabetes and intermediate hyperglycaemic states are 
summarised in Table 1.1. Impaired fasting glucose (IFG) and impaired glucose 
tolerance (IGT) are intermediate hyperglycaemic stages in the development of 
diabetes (World Health Organisation, 2006).  
Table 1.1 Diagnostic criteria for diabetes and intermediate hyperglycaemia. 
Condition Fasting plasma glucose 
mmol/L (mg/dL) 
2-h plasma glucose* 
mmol/L (mg/dL) 
Normal <6.1 (110) <7.8 (140) 
Impaired Fasting Glucose 
(IFG) 
6.1-6.9 (110-125) <7.8 (140) 
Impaired Glucose 
Tolerance (IGT) 
<7.0 (126) ≥7.8 and <11.1mmol/l 
(140mg/dl and 200mg/dl) 
Diabetes ≥7.0 (126) ≥11.1mmol/l (200mg/dl) 
*Venous plasma glucose 2 hours after 75g of glucose ingested. 
An additional means of diagnosis is the detection of glycated haemoglobin 
(HbA1c) in the blood. HbA1c reflects average plasma glucose over the previous 
eight to twelve weeks, avoiding the problem of day-to-day variability of glucose 
values. Diagnosis of diabetes can be made if the HbA1c level is greater than 6.5%, 
and a level of 5.7% to 6.4% is indicative of intermediate hyperglycaemia (World 
Health Organisation, 2011). 
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1.2.3 Pathogenesis of T2D 
Insulin is the principal hormone that regulates uptake of glucose from the blood 
into most cells. Therefore, deficiency of insulin or the insensitivity of its receptors 
plays a central role in all forms of Diabetes Mellitus. In the pathogenesis of T2D, 
insulin resistance is the symptom that occurs first in the early stages of disease 
progression. This leads to systemic hyperglycaemia, which eventually results in 
defects in insulin secretion by the pancreatic β-islet cells (Lowell and Shulman, 
2005). 
Glucose sensing by β-cells of the pancreatic islets of Langerhans is essential for 
maintaining glucose homeostasis. The β-cells act as sensors to vary insulin 
secretion to the predominant blood glucose level. Insulin allows skeletal muscle, 
liver and fat cells to take up glucose from the blood, as well as acting to promote 
glucose storage and inhibit glycogen breakdown. 
 
Figure 1.1- Glucose sensing in β-cells (Adapted from Rolland et al., 2001). 
Figure 1.1 depicts the cascade of events that result from glucose sensing by β-
cells. After docking at the GLUT-2 glucose transporter, the glucose monomer 
moves into the β-cell. It is processed through oxidative mitochondrial metabolism 
to produce adenosine-5'-triphosphate (ATP), increasing the net concentration of 
ATP in the cell at the expense of adenosine diphosphate (ADP). This increase in 
the ATP:ADP ratio of the cell results in the inhibition of an ATP:ADP-regulated 
potassium ion channel, culminating in plasma membrane depolarisation. As a 
result, voltage gated calcium channels open, causing an influx of calcium ions into 
 5 
  
the β-cell. The calcium ions signal to insulin vesicles to dock at the cell membrane 
and expel their contents into the extracellular space (Rolland et al., 2001).  
Insulin resistance (IR) is a condition where the primary insulin-responsive organs 
(skeletal muscle, the liver and adipose tissue) require higher levels of insulin for 
glucose sensing. Due to this impaired ability of the peripheral tissues to take up 
glucose, and the resulting failure of glycogen synthesis and the suppression of 
glucose production in the liver, hyperglycaemia ensues. 
There is substantial evidence indicating that mitochondrial dysfunction also plays 
a role in the pathogenesis of T2D. This occurs in a number of different ways. 
There is a systemic increase in oxidative stress in diabetic individuals as a result 
of excess production of superoxide free radicals by the mitochondrial electron-
transport system (Giacco and Brownlee, 2010; Rolo and Palmeira, 2006). Defects 
in mitochondrial fatty acid metabolism may lead to the accumulation of 
intracellular fatty acid metabolites, such as diacylglycerol and fatty acid acyl 
coenzyme As (fatty acyl CoAs). These metabolites activate protein kinase C, 
which sets in motion a cascade of events which culminates in suppression of 
insulin-stimulated glucose transport (Lowell and Shulman, 2005). Also, magnetic 
resonance spectroscopy (MRS) has been used to show that young IR progeny of 
parents with T2D have a lower ratio of type 1 (oxidative) to type 2 (glycolytic) 
muscle fibers when compared to insulin-sensitive controls. As type 1 fibers hold 
more mitochondria than type 2, it is inferred that IR individuals contain less 
muscle mitochondria. There is evidence that reduction in mitochondria numbers 
in these IR individuals is due to the down-regulation of nuclear encoded genes 
that regulate mitochondrial biogenesis, in particular peroxisome proliferator-
activated receptor co-activators 1α and 1β (PGC-1α and PGC-1β) (Chanseaume 
and Morio, 2009; Lowell and Shulman, 2005).  Mitochondrial dysfunction within 
the insulin secreting β-cells has been proposed to result in β-cell dysfunction 
through several means, and therefore the pathogenesis of T2D. Uncoupling 
protein 2 (UCP2) is an inner mitochondrial membrane protein that, when activated, 
leaks protons across the inner membrane space to uncouple the oxidative 
metabolism of glucose with ATP synthesis. It is therefore a negative regulator of 
glucose-stimulated insulin secretion, as an increase of the ATP:ADP ratio is 
required for insulin secretion, as previously mentioned. A pathogenic role in T2D 
has been suggested for UCP2 as both in vitro and in vivo models have 
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demonstrated that it is stimulated by hyperglycaemia and hyperlipidaemia, as well 
as superoxide radicals produced as a byproduct from the electron transport chain. 
β-cell mass has also been shown to be reduced in T2D individuals. While the 
cause of this reduction is still unknown, one garnered hypothesis is that it is due to 
mitochondrial mediated apoptosis, again implying mitochondrial dysfunction in 
the pathogenesis of T2D (Mulder and Ling, 2009; Kim et al., 2008; Lowell and 
Shulman, 2005).    
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1.3 Obesity 
1.3.1 Statistics 
In 2008, globally, more than 1.4 billion adults were overweight. Of these, over 
200 million men and nearly 300 million women were obese. At least 2.8 million 
people die each year as a result of being overweight or obese. Over 40 million 
preschool children were overweight in 2008. The prevalence of obesity has nearly 
doubled between 1980 and 2008 (World Health Organisation, 2012). In New 
Zealand, in 1977, 9.4% of men and 10.8% of women were considered obese. By 
2003 these figures had more than doubled; 19.9% of men and 22.1% of women 
were considered obese. Statistics are worse for Māori and Pacific peoples with 
Māori male obesity rising from 19.3% to 27.0% and Māori female obesity rising 
from 20.0% to 26.5% between 1989 and 2003. Extreme obesity has also been 
increasing. In 1977, 0.3% of males and 1.2% of females were considered 
extremely obese, which has risen to 2.2% and 3.0% respectively. Again, figures 
for Māori men are much more prevalent. Māori male extreme obesity rose from 
3.2% to 7.8% and Māori female extreme obesity held at approximately 7.0% 
between 1989 and 2003 (Ministry of Health, 2004). Like T2D, patients with 
obesity have an increased risk of CVD, which is the leading cause of death in 
people with obesity (World Health Organisation, 2012). The common association 
of obesity and CVD will be reviewed in Chapter 1.4.  
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1.3.2 Definitions of Obesity 
Obesity is defined as abnormal or excessive fat accumulation that may impair 
health. Body mass index (BMI) is a heuristic proxy for body fat defined as a 
person's weight in kilograms divided by the square of their height in meters 
(kg/m
2
).  Abdominal fat mass can vary considerably within a narrow range of total 
body fat and BMI. Therefore, waist circumference is used to complement the 
measurement of BMI, to identify individuals at increased risk of obesity related 
morbidity due to accumulation of abdominal fat. The WHO’s classification of 
body fat based on BMI and waist circumference is summarised in Table 1.2 
(World Health Organisation, 2008; World Health Organisation, 2012).  
Table 1.2 - Classifications of body fat and disease risk based on BMI and waist 
circumference. 
Classification BMI 
(kg/m
2
) 
Obesity 
Class 
Disease risk (relative to normal 
weight and waist 
circumference) 
   Men < 102 cm 
Women < 88 cm 
Men >102 cm 
Women >88 cm 
Underweight <18.5    
Normal 18.5-24.9    
Overweight 25-29.9  Increased High 
Obese 30-34.9 
35-39.9 
I 
II 
High 
Very high 
Very high 
Very high 
Extremely 
Obese 
>40 III Extremely high Extremely high 
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1.3.3 Pathogenesis of Obesity 
Evolving in an environment of scarcity, the human genome has adapted to survive 
in such conditions. However, there has been a relatively rapid change to the 
availability of foodstuffs, to the point where they are now in overabundance. Poor 
diet and sedentary lifestyle are the predominant factors that explain most cases of 
obesity; however a minority of cases may be explained through genetics and other 
illnesses (Bray, 1999). 
In most cases, obesity is simply a result of an energy imbalance, where the 
amount of energy coming into the body, through eating, grossly exceeds the 
amount of energy being expended through physical exercise. Excess energy is 
stored as adipocytes in the body’s adipose tissues. Adipose tissue functions as a 
passive reservoir of energy storage, with an inherent buffering capacity; releasing 
energy to the body when energy levels are low and absorbing it when they are 
high for later use. However, with a constant net influx of energy, there is a 
consistent setting down of adipose tissue, resulting in an abnormally high set 
down of fat deposits which results in the characteristic expansion of girth in 
individuals with obesity (Laclaustra et al., 2007).  
Over the past two decades it has been found that the adipose tissue also plays an 
important function as an endocrine organ, secreting adipocyte-derived cytokines, 
or adipokines. In addition, adipose tissue also expresses a number of receptors 
allowing it to respond to traditional hormone systems as well as the central 
nervous system (CNS). This implicates adipose tissue function as an integral 
component in an interactive endocrine network capable of communicating with 
distant organs and the CNS, and vice versa. Dysfunction of this endocrine 
component of the adipose tissue is another factor which impacts on the 
pathogenesis of obesity. Leptin is the most studied adipokine, known to play a 
number of important roles in the body. Although initially viewed as an antiobesity 
hormone, leptin's primary role is to serve as a signal of energy sufficiency, rather 
than excess, from the adipose tissue to the hypothalamus. Common forms of 
obesity are characterised by elevated circulating leptin levels, indicating that the 
body is trying to signal satiety to the brain, but the condition is not being 
ameliorated (Kershaw and Flier, 2004). This suggests that these common forms of 
obesity are consistent with a state of leptin resistance. Although the mechanism 
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for such resistance remains unknown, it has been postulated that it may result 
from the inefficient transport of leptin across the blood brain barrier (Bjorbaek 
and Kahn, 2004).  
In an area of increasing interest, recent studies have shown that leptin inhibits 
insulin secretion from the pancreatic β-cells and have anti-insulin effects on liver 
and adipose tissue. If these effects on insulin are confirmed, leptin could play a 
role similar to tumour necrosis factor-α (TNFα) and could participate in the IR 
associated with obesity and T2D (Girard, 1997). 
Grehlin, purported as the complimentary hormone to leptin, is a peptide produced 
in the stomach that is thought to be responsible for modulating short-term 
appetitive control. It acts on the hypothalamus, causing release of growth 
hormone from the pituitary. Chronic administration in rats results in obesity, and 
the fall in grehlin levels after gastric bypass surgery for obesity has been posited 
for the suppression of appetite seen after such operations (Flier, 2004).  
Defects in the pro-opiomelanocortin receptor system, the peroxisome proliferator-
activated receptor-gamma, the agouti-related peptide, hypothalamic injury 
following craniopharyngioma, and several rare genetic syndromes such as Prader-
Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome, and MOMO syndrome 
are also associated with human obesity. However, for most patients, it is not 
possible to connect obesity to any one specific cause (Bray, 1999).  
An emerging trend is that obese individuals exhibit increased oxidative stress.  Fat 
accumulation has been shown to positively correlate with systemic oxidative 
stress in both humans and mice. As the production of reactive oxygen species 
(ROS) increased, there was increased expression of NADPH oxidase and 
decreased expression of antioxidative enzymes. This would perhaps suggest that 
some degree of mitochondrial dysfunction may play some role in the pathogenesis 
of obesity (Furukawa et al., 2004).  
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1.4 T2D and Obesity 
T2D and obesity are related diseases, as most patients with T2D are obese. 
However, most obese individuals do not have T2D. The causal interplay between 
the two is very complex and not fully understood. Whatever the relationship 
between T2D and obesity may be, it is recognised that both disease states lead to 
similar pathophysiological complications (Eckell et al., 2011).   
Metabolic syndrome is a combination of medical disorders that occur together to 
increase the risk of developing CVD. The two major disorders that contribute to 
metabolic syndrome are T2D and obesity. Metabolic syndrome is characterised 
with a number of pathophysiological conditions including hyperglycaemia, 
dyslipidaemia, abdominal obesity, and hypertension (Brownlee, 2001).   
1.4.1 Complications of T2D  
Diabetes is associated with pathophysiological conditions such as hyperglycaemia, 
hyperinsulinaemia, dyslipidaemia, abdominal obesity, raised blood pressure, a 
low-grade pro-inflammatory state, and atherosclerosis (Bailey, 2008). As 
previously mentioned, T2D patients have an increased risk of CVD, which is 
responsible for 50-80% of deaths in people with diabetes (World Health 
Organisation, 2011; Zarich, 2009). CVD is a collective term for both 
microvascular and macrovascular diseases. Microvascular diseases include 
various neuropathies, end-stage renal disease, and blindness; while macrovascular 
diseases refer to atherosclerotic events such as stroke, myocardial infarction, and 
limb amputation (Brownlee, 2001). 
1.4.2 Complications of Obesity 
A number of the major diseases associated with obesity have long been known 
and include hypertension, atherosclerosis, and diabetes, as well as certain types of 
cancer. Less well-known complications include hepatic steatosis, gallbladder 
disease, pulmonary function impairment, endocrine abnormalities, obstetric 
complications, trauma to the weight-bearing joints, gout, cutaneous disease, 
proteinuria, increased haemoglobin concentration, and possibly immunologic 
impairment (Bray, 1982). In addition, the site of obesity has long been known to 
impact on the severity of obesity related complications. Individuals with upper 
body segment obesity, that being abdominal obesity, have been found to be much 
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more prone to complications including glucose intolerance, hyperinsulinemia, and 
hypertriglyceridemia when compared to individuals with lower body segment 
obesity (Kissebah et al., 1982). Much like in T2D, patients with obesity have an 
increased risk of CVD, which is also the leading cause of death in people with 
obesity (World Health Organisation, 2012). 
1.4.3 CVD Complications 
CVDs are the primary life threatening complication of T2D and obesity. The high 
levels of circulating free fatty acids (FFAs) associated with these disease states 
encourage the liver to produce more ‘bad’ low-density lipoprotein (LDL) 
cholesterol, while reducing levels of ‘good’ high-density lipoprotein (HDL) 
cholesterol. This alteration in relative cholesterol levels helps to promote 
atherosclerosis, which may culminate in CVD if left untreated. High circulating 
FFA levels also have deleterious effects on the body’s blood vessels, causing 
constriction and hypertension. It also induces a signal to inflammatory factors, 
stimulating their recruitment, which can result in systemic, low-grade 
inflammation of the circulatory system’s endothelium (Jensen, 2006). 
Early stages of atherosclerotic development require recruitment of monocytes and 
their ultimate differentiation into macrophages (Ludewig and Laman, 2004; 
Beekhuizen and van Furth, 1993). Monocytes are required to cross the vascular 
endothelium for routine immunological surveillance of tissues and their entry into 
inflamed sites. This process of transendothelial migration, or diapedesis, initially 
involves tethering of monocytes to the endothelium, followed by loose rolling 
along the vascular surface. There is then the establishment of firm adhesion to the 
endothelium via interactions between the monocyte and a number of cellular 
adhesion proteins expressed on the endothelial cell surface. These adhesion 
proteins include vascular cell adhesion molecule-1 (VCAM-1), integrins and CD 
receptors, occurring at different steps along the migration. A gradient of 
chemoattractants is responsible for driving the subsequent monocyte migration 
into the endothelial intima. One of the major chemokines responsible for 
monocyte migration is monocyte chemoattractant protein-1 (MCP-1), which 
interacts with its receptor CCR2, located on the monocyte surface. After 
penetrating the endothelial basement membrane, the monocytes may migrate 
through the extracellular tissue matrix and differentiate into macrophages. 
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Macrophages are known to express a number of scavenger receptors, including 
CD36, which bind to modified forms of LDLs. Common modifications include 
oxidation and glycation (also referred to as non-enzymatic glycosylation). When 
macrophages take up these forms of LDLs they undergo several alterations, 
namely their morphology. They are termed foam cells due to their abnormal 
appearance under the microscope that resembles foam. Clusters of foam cells 
represent the early stages of the formation of atherosclerotic lesions. The foam 
cells amplify inflammatory signals from the site of the lesion through the 
production of ROS, cytokines and tissue damaging proteins, including the matrix 
metalloproteinases (MMPs). As foam cells continue to aggregate along with T 
helper cells and skeletal muscle cells, the lesion progresses and may lead to a 
thrombotic or embolic event. If the lesion were to get to a sufficient size it could 
occlude the vessel. If the atherosclerotic lesion were to rupture, the plaque could 
be carried through the bloodstream to any number of smaller capillaries which it 
could occlude. Depending on the site of blockage, a ruptured atherosclerotic 
lesion could result in myocardial infarction, stroke, or limb amputation (Maslin et 
al, 2005; Ludewig and Laman, 2004; Libby, 2002).  
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1.5 Heat Shock Proteins 
Heat shock proteins (HSPs) are a group of highly conserved proteins found in all 
cells of all organisms in prokaryotic and eukaryotic life. They were first observed 
in 1962 by Ritossa, when a lab worker accidentally increased the incubation 
temperature of the fruit fly drosophila. When examining the chromosomes, 
Ritossa found a "puffing pattern" which was indicative of the elevated gene 
transcription of an unknown protein. This was later described as the ‘Heat Shock 
Response’ and the unknown proteins as the ‘Heat Shock Proteins’ (Ritossa, 1996). 
The enhanced synthesis of these proteins immediately after subjecting cells to a 
proteotoxic stress, such as heat shock, was first reported for drosophila cells in 
1974, and the universality of the response, from bacteria to human, was 
recognized shortly thereafter (Schlesinger, 1990).  HSPs are actually 
constitutively expressed, and have two main intracellular roles: a molecular 
chaperone function, where they act to mediate the folding, assembly or 
translocation across the intracellular membranes of other polypeptides; and a role 
in protein degradation, making up some of the essential components of the 
cytoplasmic ubiquitin-dependent degradative pathway (Burel et al., 1992). 
However, when exposed to a proteotoxic stressor, HSP expression is induced to 
prevent cellular damage and stave off apoptosis.  
HSPs can be classified into six families, based on their molecular mass: the small 
HSPs (sHSP), HSP40, 60, 70, 90, and HSP110 (Table 1.3). 
Table 1.3 Major mammalian HSP families (Adapted from Habich and Burkart, 2007). 
Families Size (KDa) Prominent members Localisation 
sHSPs 12-43 B-crystallin 
HSP27 
Cytoplasm 
Cytoplasm, nucleus 
HSP40 ~40 HSP40 Cytoplasm, nucleus 
HSP60 ~60 HSP60 
TCP1 
Mitochondria 
Cytoplasm 
HSP70 ~70 HSP70 
HSC70 
Grp78/BiP 
Cytoplasm 
Nucleus 
Cytoplasm, ER 
HSP90 ~90 HSP90 (α and β) 
Gp96 
Cytoplasm 
ER 
HSP110 ~110 HSP110 Cytoplasm 
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In more recent times, HSPs have been detected extracellularly, both on the cell 
surface and in the extracellular space. When expressed in these locations, HSPs 
take on an immunoregulatory role. Members of the HSP60 and HSP70 families in 
particular have been established as playing stimulatory roles of both the innate 
and adaptive immune systems when in these locales.   
1.5.1 The HSP60 Family 
Proteins belonging to the HSP60 family have a molecular weight of 
approximately 60 KDa. They also have high sequence homology between species 
with HSP60s of bacterial origin having homology higher than 97% while 
prokaryotic and human HSP60 show over 70% homology. 
One of the most studied members of the HSP60 family is the E. coli GroEL 
protein. It is well documented for playing a crucial ATP-dependent role in protein 
folding along with its cofactor GroES, also referred to as HSP10. Crystal 
structures of GroEL show that it is an oligomer that forms a complex arranged as 
two stacked heptameric rings (Cheng et al., 1990). This dual heptameric structure 
forms a large central cavity, which is where unfolded proteins bind through 
hydrophobic interactions (Fenton et al., 1994).  
The HSP60 subunit consists of three domains: the equatorial, intermediate, and 
apical domains. The equatorial domain contains the binding sites for ATP and the 
second heptameric ring. The intermediate domain fixes the equatorial and apical 
domains together. When ATP is bound, the intermediate domain undergoes a 
conformational change which exposes the hydrophilic regions of the protein, 
ensuring fidelity in protein binding. HSP10 binds to the apical domain of the 
ATP-bound active HSP60 complex, acting as a dome-like cap. This allows the 
central cavity to enlarge and aids in protein folding (Ranford et al., 2000). 
The amino acid sequence of HSP60 contains a series of G repeats at the C-
terminal, although the structure and function of this sequence has not been 
conclusively defined. Like other nuclear-encoded mitochondrial proteins, the N-
terminal of HSP60 contains a leader sequence of hydroxylated amino acids. This 
N-terminal presequence directs the protein into the mitochondria. Upon 
translocation to the organelle the leader sequence is cleaved off (Gupta, 1995).  
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In eukaryotes, HSP60 is found in the chloroplasts of plants as well as the 
mitochondria and cytoplasm of mammalian species. While HSP60 in 
Saccaromyces cerevisiae and chloroplasts exist and function as tetradecamers, in 
mitochondria HSP60 typically exists in a dynamic equilibrium between its 
constituents; monomers, heptamers and tetradecamers (Habich and Burkart, 2007). 
In the presence of ATP, mitochondrial HSP60 forms the tetradecamer complex 
and it dissociates into its monomers in its absence (Levy-Rimler et al., 2001). In 
contrast, cytosolic HSP60 forms heterooligomeric ring structures and assists 
folding of cytoskeletal proteins, such as actin and tubulin (Llorca et al., 2000). 
HSP60 expression been found to be induced in response to mitochondrial stress, 
and therefore its upregulation is a good indicator of mitochondrial impairment. 
This is in contrast to other HSPS, such as HSP70, where induced expression is an 
indicator of a general cell stress (Martinus et al., 1996)  
More recently, HSP60 has also been documented to exist outside the cell. HSP60 
has been found on the cell surface and extracellularly, such as in human 
circulation. When HSP60 is localised in such locations it plays an 
immunoregulatory role, and a possibility for cross-reactivity with microbial 
HSP60 has also been theorised. The localisation and function of extra-cellular 
HSP60 will be discussed in greater detail in later sections.  
1.5.2 The HSP70 Family 
Proteins belonging to the HSP70 family have a molecular weight of 
approximately 70 KDa. Eukaryotic organisms express several slightly different 
HSP70 proteins. All share the same common domain structure, but each has a 
unique pattern of expression or subcellular localization. These include HSC70, 
HSP70, BIP, and mtHSP70 (Tavaria et al., 1996).  
HSP70 consists of three major functional domains. The N-terminal contains an 
ATPase domain, binding ATP and hydrolising it to ADP. This action results in 
conformational changes in the other two domains. The intermediate substrate 
binding domain contains a groove with an affinity for neutral, hydrophobic amino 
acid groups up to seven residues in length. The C-terminal domain is rich in alpha 
helices which act to enclose the substrate binding domain. When ATP is bound 
the helical ‘lid’ opens to bind and release peptides with relative speed. When ADP 
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is bound the lid closes, tightly binding peptides to the substrate binding domain 
(Flaherty et al., 1990).  
HSP70 plays an important role in preventing the aggregation of newly formed 
proteins in the cytosol. As newly synthesised proteins emerge from the ribosomes, 
the intermediate substrate binding domain of HSP70 recognizes sequences of 
hydrophobic amino acid residues and interacts with them. The presence of 
peptides in the binding domain stimulates the ATPase activity of the N-terminal 
domain. When ATP is hydrolysed to ADP, the binding pocket of HSP70 closes, 
tightly binding and trapping peptide chain. By binding partially synthesized 
peptide sequences, HSP70 prevents them from aggregating and being rendered 
non-functional. Once the entire protein is synthesised, nucleotide exchange factors 
stimulate the release of ADP and binding of a new ATP molecule, releasing the 
peptide from the substrate binding domain of HSP70. The protein is then free to 
undergo spontaneous folding, or to be transferred to other chaperones for further 
processing. In much the same way, HSP70 also aids in intermembrane transport of 
proteins by stabilizing them in a partially folded state (Wegele et al., 2004; 
Tavaria et al., 1996).  
HSP70 proteins also act to protect cells from a number of stressors. These 
stressors would normally act to damage proteins, causing partial unfolding and, 
potentially, aggregation. By temporarily binding to hydrophobic residues exposed 
by the stress, HSP70 prevents these partially denatured proteins from aggregating, 
and allows them to refold once the stress response has passed (Tavaria et al., 
1996).  
Finally, HSP70 also directly inhibits apoptosis by blocking the recruitment of 
procaspase-9 to the apoptosome complex (Beere et al., 2000). 
Like HSP60, HSP70 has also been found to exist outside the cell, both surface 
bound and in the extracellular milieu. It too plays an immunoregulatory role, 
being reported to play roles in antigen binding and presentation to the immune 
system (Nishikawa et al., 2008).  
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1.5.3 Regulation of HSPs 
HSPs can make up to 5-10% of the total protein content in optimal growing 
conditions. However, the synthesis of these proteins can be induced to make up to 
15% of total protein content by stresses that induce protein unfolding, misfolding, 
aggregation, or a flux of newly synthesized non-native proteins (Pockley, 2003). 
The inducible HSP component is regulated by heat shock factors (HSFs). These 
are transcription factors are that are usually negatively regulated but are activated 
upon cellular stress (Morimoto, 1993). When activated, these activators bind 
specifically to heat shock sequence elements (HSE) throughout the genome 
(Guertin and Lis, 2010). The HSEs are highly conserved from yeast through to 
humans (Guertin et al., 2010). Only one HSF has been identified in 
Saccharomyces cerevisiae and Drosophila melanogaster, however a number of 
HSFs exist in vertebrates and plants. This suggests that these HSF isoforms have 
diversified and specialised in these species (Pirkkala et al., 2001).  
HSF-1 is the major regulator of HSP transcription in eukaryotes. Although sharing 
40% structural homology to HSF-2, HSF-1 functions in response to stress stimuli 
whereas HSF-2 activates under early embryonic development, differentiation and 
by inhibition of ubiquitin-dependent proteasome (Pirkkala et al., 2001). In the 
absence of cellular stress, HSF-1 is inhibited due to its association with HSPs and 
is therefore maintained in an inactive state. For instance, HSP70 has been shown 
to play a role in HSF-1 deactivation, as has the formation of a heterocomplex 
involving HSP90, although each modulates different steps of the HSF-1 
activation-deactivation pathway. Additionally, an 8.5kDa nuclear protein termed 
heat shock factor 1 binding protein (HSF1BP) has also been found to hinder the 
oligomerisation process of HSF-1 monomers. These several means of deactivating 
HSF-1 highlight the importance of HSPs, as their transcription is so tightly 
regulated in a number of ways by cells.  
If and when a cellular stress does occur, the HSPs bind to any misfolded proteins, 
and subsequently dissociate from HSF-1. This allows the HSF-1 monomers to 
oligomerise and form active trimers, regaining their DNA binding activity. The 
trimers undergo stress-induced serine phosphorylation and are translocated to the 
nucleus (Prahlad and Morimoto, 2008).  Upon nuclear localisation, HSF-1 binds 
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to the HSE situated upstream of heat shock responsive genes, which results in 
HSP gene transcription.  
A number of other HSF isoforms have also been identified. HSF3 is an avian HSF 
and it too is a stress responsive transcription factor. HSF4 is the most recently 
discovered mammalian HSF, and has been found to be restricted to certain tissues. 
While its specific role is still unclear, it shows properties of a transcription 
repressor (Pirkkala et al., 2001). 
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1.5.4 Extracellular HSP60 Locations 
While HSP60 is typically localised in the mitochondria, it has also been found to 
exist on the surface of cells as well as in the extracellular milieu. This has been 
found across both prokaryotic and eukaryotic cells alike, under both normal and 
stress conditions.  
1.5.4.1 Surface HSP60 Expression 
HSP60 has been found to be expressed on the surface of cells. In 2000, Newman 
and Crooke used immunogold cryothin-section electron microscopy and 
immunofluorescence to detect the localisation of HSP60 in E. coli. They found 
that 16% of the labelled GroEL proteins were located in the membrane fraction 
under normal conditions, and that the density of gold-bound GroEL was in fact 
higher in the membrane region than in the cytosol.  
In 1997, Soltys and Gupta used immunogold electron microscopy on various 
mammalian cell lines to detect HSP60. They found that 15-20% of the HSP60 was 
localised in extramitochondrial sites. These sites included the foci of the 
endoplasmic reticulum, on the cell membrane and other unidentified vesicles. The 
group went on to confirm cell membrane localisation by biotin labelling of the 
plasma membrane proteins, followed by immunoprecipitation and Western blots. 
Using much of the same methodology, Cicconi and colleagues found that 
approximately 10% of total cell HSP60 was expressed on the cell surface of 
Daudi cells (Cicconi et al., 2004). 
More recently, Pfister and colleagues (2005) used confocal laser scanning 
microscopy (CLSM) and flow cytometry to investigate the surface expression of 
HSP60 in human umbilical venous endothelial cells (HUVECs). The CLSM 
revealed that there was no production of HSP60 on the surface of unstressed cells. 
However, after a heat shock treatment, consisting of a 42°C treatment for 30 min 
and a 6 hour recovery, a significant portion of cells (10.9 ± 3.6%) had HSP60 
expressed on the cell surface. This is comparable to the 9.5% they detected by 
flow cytometry. The number of cells that had surface expression of HSP60 had 
also increased from 1.1% to 9.5% following the heat stress (Pfister et al., 2005). 
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1.5.4.2 Extracellular HSP60 Expression 
In the last few decades, it has become increasingly well established that HSP60 
exists not only intracellularly, but also in the extracellular space and in the 
circulatory system. HSP60 has been detected by enzyme-linked immunosorbant 
assay (ELISA) in the culture media of cells which have been stressed (Liao et al., 
2000). In humans, circulating HSP levels have been found in systemic circulation 
of both healthy subjects and those experiencing disease states. HSP60 was first 
detected in the serum of normal individuals and elevated levels in individuals with 
hypertension by Pockley and colleagues in 1999, and has been further shown to be 
present in saliva (Fabian et al., 2003). Circulating HSP60 has even been 
documented in healthy teenagers, for which a possible association with 
endothelial dysfunction has been suggested (Halcox et al., 2005). Studies of 
atherosclerosis have also reported a correlation between serum HSP60 levels and 
arterial intima-media thickness, suggesting that circulating levels of HSP60 may 
be associated with vascular injury (Ellins et al., 2008; Pockley et al., 2003). 
Circulating HSP60 levels have similarly been found to be decreased with aging 
(Tsan and Gao, 2004), and increased in disease states characterised by chronic 
stress, such as T2D and obesity, which will be discussed in greater detail in 
Chapter 1.5.7.  
 1.5.4.3 Secretory Pathway 
How HSPs are secreted into the extracellular milieu is yet to be fully characterised. 
At present, it is believed that HSPs are actively secreted from cells, rather than by 
necrosis. The postulated pathways surround exosomes and lipid rafts. Blocking 
common protein secretory pathways has no effect on diminishing HSP60 release. 
However, using exosome and lipid raft inhibitors has been used to some success, 
decreasing the amount of HSP60 released from cells.  Lipid rafts are recognised as 
playing an important role in exosome formation, so it can therefore be postulated 
that either exosomes and lipid rafts, or exosomes alone, are the secretory pathway 
for HSPs (Merendino et al., 2010; Gupta and Knowlton, 2006).    
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1.5.5 Extracellular HSP60 Function 
HSPs play the role of molecular chaperones when situated intracellularly. 
However, when expressed extracellularly, HSPs play an important 
immunoregulatory role, impacting on both the innate and adaptive immune 
systems. A number of bacterial and mammalian HSPs have had their effect on the 
immune system characterised, as depicted in Table 1.4 and Table 1.5 respectively. 
Early work investigating the immunogenic properties of recombinant human 
HSPs found they could elicit a number of immune responses through the 
activation of the conserved Toll-like receptor (TLR) family. The resulting 
activation of the downstream Toll/Interleukin-1 (IL-1) receptor pathway led to the 
activation of nuclear factor-κB (NF-κB) and cytokine release; the patterns of 
which show close similarities to that of bacterial lipopolysaccharides (LPS). It 
was hence concluded that many of the reported immunogenic properties of HSPs 
were actually due to endotoxin contamination. There is therefore a danger that the 
founding data on HSPs and the immune system are actually false positives, and 
work done since has been based upon incorrect data. To correct this, a number of 
counter measures have since been introduced to overcome the problem of 
endotoxin contamination, including: purifying HSPs from eukaryotic hosts, using 
a limulus amebocyte lysate (LAL) assay to measure endotoxin levels, the treating 
of HSPs with polymyxin B (a potent binding agent of LPS), the heat denaturation 
of HSPs, and breeding lineages of mice defective for the recognition of LPS (van 
Wijk and Prakken, 2010; Tsan and Gao, 2009; Gao and Tsan, 2003; Bausinger et 
al., 2002). 
More recent studies, free of endotoxin contamination, have reaffirmed the 
immunoregulatory role that HSPs play when located extracellularly.  HSPs 
achieve this in several ways, including binding antigenic peptides and mediating 
their presentation to the major histocompatibility complex (MHC) proteins, acting 
as an endogenous danger signal under cellular stress and tissue damage, and 
binding to pathogen-associated molecular pattern (PAMP) molecules which 
culminates in signalling through pattern recognition receptors (PRRs) (Osterloh 
and Breloer, 2008). 
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Table 1.4. Activation of innate immune cells by microbial heat-shock proteins (Adapted 
from Wallin et al., 2002). 
Heat-Shock Protein Cell Type Effect 
M. leprae HSP65 Monocytes (THP-1) Production of TNF- α, IL-6 and IL-8 
M. tuberculosis HSP65 Monocytes (THP-1) CD14-dependent production of TNF-
α and IL-1β 
M. bovis HSP65 Monocyte-derived 
macrophages 
Production of TNF-α and IL-1β 
L. pneumophila HSP60, E. coli 
GroEL, M. leprae HSP65, M. 
bovis HSP65 and M. 
tuberculosis HSP70 
Peritoneal macrophages Induction of transcription of TNF-α, 
IL-1α, IL-1β, IL-6 and GM-CSF 
mRNA, and increase in supernatant 
IL-1 bioactivity 
Mycobacterial HSP65 Peritoneal macrophages Production of TNF-α, IL-6 and 
reactive nitrogen intermediates 
E. coli GroEL Calvarial bone Bone-resorbing activity 
L. pneumophila HSP60 Macrophages PKC- and cell-surface-receptor-
dependent production of IL-1 
L. pneumophila HSP60, M. 
bovis HSP65 and M. 
tuberculosis HSP71 
Macrophages Production of IL-12 
Recombinant M. bovis HSP65 HUVECs Increased adhesiveness to monocytes 
and granulocytes, and up-regulation 
of expression of E-selectin (CD62E), 
VCAM-1 (CD106) and ICAM-1 
(CD54) 
E. coli GroES, GroEL and 
DNAk 
Monocytes Production of TNF-α, IL-6 and GM-
CSF 
 HUVECs Production of IL-6 and GM-CSF, 
and up-regulation of expression of E-
selectin, ICAM-1 and VCAM-1 
Recombinant chlamydial 
HSP60 
Vascular endothelium, 
smooth muscle cells and 
macrophages 
Up-regulation of expression of 
adhesion molecules, production of 
IL-6 and activation of NF-κB 
Recombinant chlamydial 
HSP60 
Macrophages and 
dendritic cells 
Activation of the Toll/IL-1 signalling 
pathway 
Abbreviations: E. coli, Escherichia coli; GM-CSF, granulocyte–macrophage colony-stimulating 
factor; HSP, heat-shock protein; HUVEC, human umbilical-vein endothelial cell; ICAM-1, 
intracellular adhesion molecule 1; IL, interleukin; L. pneumophila, Legionella pneumophila; M. 
bovis, Mycobacterium bovis; M. leprae, Mycobacterium leprae; M. tuberculosis, Mycobacterium 
tuberculosis; NF-κB, nuclear factor κB; PKC, protein kinase C; TNF-α, tumour necrosis factor α; 
VCAM-1, vascular cell adhesion molecule 1. 
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Table 1.5. Activation of innate immune cells by mammalian heat-shock proteins 
(Adapted from Wallin et al., 2002). 
Heat-Shock Protein Cell Type Effect 
Recombinant HSP60 and 
HSP70 
Macrophages Production of IL-12 
HSP70 Promonocytes (U-937) Activation of potassium channels 
and increased expression of the 
differentiation markers CD11c and 
CD23 
Recombinant HSP60 Vascular endothelium, 
smooth muscle cells and 
macrophages 
Up-regulation of expression of 
adhesion molecules, production of 
IL-6 and activation of NF-κB 
Recombinant HSP60 Macrophages Production of TNF-α, NO and IL-12 
HSP70 with or without bound 
peptide 
Splenocytes Production of IL-1β and TNF-α 
Recombinant HSP70 Dendritic cells Production of IL-1β, IL-6, IL-12 and 
TNF-α, and maturation of dendritic 
cells 
gp96 Dendritic cells Maturation of dendritic cells, and 
production of IL-12 and TNF-α 
HSP70, HSP90 and gp96 Macrophages and 
dendritic cells 
Maturation of dendritic cells, 
production of IL-1β, IL-6, IL-12 and 
TNF-α, and activation of NFκB 
gp96 Dendritic cells in vivo In vivo induction of maturation and 
migration of CD11c+ cells 
Recombinant HSP60 Macrophages and 
dendritic cells 
Activation of the Toll/IL-1 signalling 
pathway 
HSP70 Dendritic cells Maturation of dendritic cells 
Abbreviations: HSP, heat-shock protein; IL, interleukin; NF-κB, nuclear factor κB; NO, nitric 
oxide; TNF-α, tumour necrosis factor α. 
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1.5.5.1 HSPs as Binding Agents of Antigenic Peptides 
Cytosolic HSPs, including HSP70, HSP90 and gp96, play important roles in 
antigen presentation, cross-presentation, and tumour immunity. Antigen 
presenting cells (APCs) internalise the HSP/peptide complex through CD91-
mediated endocytosis, resulting in MHC I presentation and cytotoxic T 
lymphocyte induction (Tsan and Gao, 2004). This has a number of significant 
implications for the design of vaccines and therapeutics for infectious diseases 
and cancer.  However, as HSP60 has not been implicated in this mechanism, it 
will not be discussed further in this review.  
 
1.5.5.2 HSP60 as a Danger Signal 
There are several theories have been proposed relating to regulation of the 
immune system: Burnet’s Self-Nonself (SNS) theory, Janeway's Infectious 
Nonself (INS) theory, and Matzinger's Danger theory. Each theory has their fair 
share of novel and controversial elements, but each has merit.  
Frank Burnet’s SNS theory states that an immune response is based on the 
discernment of “self” and “nonself” antigens. It suggests that early lymphocytes 
express multiple copies of a distinctive receptor that recognises foreign antigens 
to initiate an immune response. As these lymphocytes clonally expand, self-
reactive lymphocytes are quickly erased (Burnet, 1959). However, the SNS theory 
has since been modified, as it is now known that the recognition of “nonself” 
alone is not sufficient to trigger an immune response.  
Charles Janeway’s INS theory, also referred to as the Extended-SNS theory, states 
that the activation of an immune response depends on the discrimination between 
“infectious nonself” and “noninfectious self” by APCs. APCs contain a vast 
assortment of PRRs specific for conserved PAMPs expressed by pathogens. Upon 
PAMP/PRR association, APCs become activated, producing costimulatory signals, 
and presenting foreign antigens to T cells (Janeway, 1992). Janeway’s theory has 
been supported by the discovery of evolutionary conserved TLRs, of which the 
family consists of 10 members. These receptors act as PRRs as they recognise 
components of bacteria, fungi and viruses to activate APCs (Akira et al., 2001). 
Both Burnet’s SNS theory and Janeway’s INS theory have several shortcomings 
however, including describing events such as transplant rejection, autoimmunity, 
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and tumours, where “nonself” or “infectious nonself” is absent, as identified by 
Matzinger (1998). 
Polly Matzinger’s Danger theory states that regardless of the foreign nature of a 
particular compound, what really determines if an immune response occurs is if 
that particular compound causes damage or not. It may be seen as an extension of 
immune signals by “self” molecules that act as an endogenous danger signal. 
Danger signals are thought to be conserved, profuse and ubiquitously expressed 
“self” molecules that are normally housed intracellularly, in healthy cells. 
However, if the cells are injured, infected, abnormally stressed or necrotic, the 
danger signal may be released into the extracellular space. Once there, the danger 
signals are suspected of being recognised by APCs, mediating activation of the 
costimulatory signals which initiate an adaptive immune response. In this regard, 
the Danger theory suggests that endogenous signals that originate from cells 
experiencing injurious or stressful conditions are utilised to induce an effective 
immune response (Osterloh and Breloer, 2008; Matzinger, 1998). 
HSPs, being expressed abundantly and ubiquitously, present themselves as a good 
candidate as endogenous danger signals as they are up-regulated during times of 
various cellular stresses, can be expressed on the cell surface, and can be actively 
secreted. As such, they may become accessible to immune cells during times of 
cellular danger. Many HSPs, from a variety of preparations, have been shown to 
be potent activators of the innate immune system. Such results include the 
production of a range of cytokines, including TNFα, IL-1, IL-6, IL-12, as well as 
the release of nitric oxide (NO) from monocytes, macrophages and APCs. An 
ability of HSPs to induce the maturation of APCs has also been observed, as 
demonstrated by the up-regulation of MHC class I and II molecules. (Tsan and 
Gao, 2004; Chen et al., 1999).  
There is still considerable debate surrounding whether HSP60 is able to induce 
such immunoregulatory responses without endotoxin co-stimulation derived from 
LPS contamination. However, more recent studies still provide evidence for an 
immunomodulatory role of HSP60 in the innate immune response. Osterloh and 
colleagues have demonstrated that HSP60 has the ability to modulate immune cell 
function through the use of transgenic cell lines which express HSP60 on the cell 
surface. This surface HSP60 was found to induce the maturation of murine APCs 
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as well as upregulate the expression of interferon-α (IFNα). The signalling 
pathway was also found to enhance T cell activation, and is a distinct signalling 
pathway to that which is induced by LPS (Osterloh et al., 2007; Osterloh et al., 
2004). Furthermore, these effects of HSP60 differ from its intracellular function in 
that they do not require peptide binding, ATP hydrolysis, cofactors or the 
assembly of a protein complex (Tsan and Gao, 2004).  
1.5.5.3 HSP60 and PAMP-Signalling 
Accumulating evidence suggests that HSPs are capable of binding PAMP 
molecules, and therefore modulate PAMP-induced stimulation of the immune 
system. Human and murine surface expressed HSP60 has been shown to bind 
tritium labelled LPS in a binding pattern that is specific, saturable, and also able to 
be competed for with unlabelled LPS. Furthermore, an LPS binding region has 
been identified on HSP60. Treatment with specific antibodies for this epitope has 
been shown to inhibit LPS binding, further supporting a role for HSP60 as an LPS 
binding protein (Habich et al., 2005). HSPs have been shown to associate with 
PRRs. Extracellular HSP60 has been shown to bind to macrophages and dendritic 
cells (DCs) in distinct areas that co-localise with the PRR CD14 (Osterloh et al., 
2007). 
It has been shown that highly purified HSP60 and HSP70 do not induce the 
release of pro-inflammatory cytokines such as TNFα (Gao and Tsan, 2003; 
Bausinger et al., 2002). It is rather believed that HSP binding to PAMP has a 
synergistic effect on inflammatory stimulation. Evidence for this includes that the 
addition of recombinant HSP60 and HSP70 has been shown to enhance LPS-
induced TNFα release in macrophages (Zheng et al., 2004). Other studies have 
shown that pre-incubation of LPS with HSP60 or HSP70 causes a dose-dependent 
increase in TNFα secretion from peripheral blood-derived mononuclear cells 
(PBMCs) (Bangen et al., 2007).  Pre-incubation with LPS has also been shown to 
enhance murine cell surface HSP60, LPS-induced IL-12p40 production in 
peritoneal macrophages and IFNγ release from T cells in a synergistic manner 
(Osterloh et al., 2007). 
When considered together, this evidence suggests that HSP60 plays a role as a 
complex modulator of the innate immune system, while also influencing adaptive 
immune responses. HSP60 can act as an intracellular danger signal as well as a 
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sensor for PAMPs, such as LPS, providing an increased efficacy to immune 
responses. The additional effect of HSP60 on cytokine expression has also been 
purported to be a contributing factor in the pathogenesis of both autoimmune 
diseases and chronic inflammation (Tsan and Gao, 2004). 
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1.5.6 Receptor and Signalling Pathway for HSP60 
The search for the HSP60 receptors is a controversial topic due to the well 
documented problems surrounding the possibility of endotoxin contamination 
even after several control methods, as well as the LPS-binding nature of HSP60. 
Because of this, it has been unclear whether HSP60 shared the same receptors as 
LPS, primarily CD14 and TLR4. As HSP70 has been shown to bind to various 
receptors such as CD14, TLR4, LOX-1, CD40 and CCR5 (Binder et al. 2004), it 
has been proposed that HSP60 may also exhibit a similar non-specific quality in 
receptor binding, or that some receptors have been mistakenly identified due to 
the aforementioned problems ( Henderson and Mesher, 2007; Binder et al., 2004).  
HSP60 has been shown to bind to a number of different cell types. Using flow 
cytometry, fluorescence-labelled human HSP60 has been shown to bind to murine 
macrophages at submicromolar concentrations. Furthermore, the binding is 
saturable and cannot be competed for by unrelated control proteins, confirming 
characteristics of specific ligand-receptor interactions. Additionally, HSP70, 
HSP60 and gp96 could not compete, and HSP60 binding still occurred in the 
absence of surface TLR4.  Confocal microscopy also confirmed that HSP60 binds 
with endothelial and DCs (Habich et al., 2002).  However, binding of human 
HSP60 to macrophages could not be competed for by HSP60 of hamster or 
bacterial origins. This would suggest a heterogeneous nature for the receptor 
binding of HSP60 (Habich et al., 2003). 
The CD14 signalling complex has been found to be necessary but not sufficient 
for responsiveness to human HSP60 in Chinese hamster ovary (CHO) cells and 
human CD14-transfected astrocytoma cells. These are cells which would normally 
lack a response to LPS (Kol et al., 2000). This is of particular interest as TLRs 
have been described as components of the CD14 signalling pathway, of which 
TLR4 has been characterised as a co-receptor for LPS. The same group also found 
that p38 mitogen-activated protein kinase (MAPK) in PBMCs was activated by 
HSP60, much like LPS. As a result NF-κB was found to be activated, which 
culminated in the release of IL-6 (Triantafilou and Triantafilou, 2002).  
Chlamydial and human HSP60 have been shown to induce a number of stress-
activated protein kinases in murine macrophages, namely p38, c-Jun N-terminal 
kinases1/2 (JNK1/2), the mitogen-activated protein kinases (ERK1/2), and the I-
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κB kinase (IKK).  The activation of these protein kinases was found to be 
mediated by TLR2 and TLR4, as cells with defective versions of these receptors 
exhibited a diminished response. Additionally, the activation of this pathway was 
perturbed when cells were treated with an inhibitor known to disrupt endocytosis 
(Vabulas et al., 2001). 
More recently, experiments using genetically engineered eukaryotic cells have 
been used to investigate the signalling pathway of HSP60.  Cells engineered to 
express surface HSP60 have revealed that the signalling is independent of TLR4, 
and that previous data that suggested otherwise was due to PAMP-associated TLR 
signalling.  Pure HSP60, that is to say HSP60 absent of endotoxin contamination, 
was found to not result in the expression of a number of previously reported 
cytokines such as IL-6, IL-12 and TNFα. However, the expression of IFNα was 
found to be up-regulated in APCs, which was required for the activation of T cells. 
Membrane bound HSP60 was also observed to enhance the release of IFNγ in 
TLR4-mutant APCs during T cell co-stimulation, and this effect was not observed 
after treatment with LPS (Osterloh et al., 2008). 
Other groups have used novel methods to investigate HSP60 receptors, such as 
Henderson and Mesher (2008). They ran murine whole cell lysate through a 
column immobilized with Mycobacterium tuberculosis Cpn60.1 and analysed the 
bound fraction by peptide mass fingerprinting. The best matched candidates for 
Cpn60.1 were found to be BiP, an HSP70 localised in the lumen of the 
endoplasmic reticulum; VCAM-1 precursor, and polycomb protein SUZ 12. It 
should be emphasised that the hypothesised receptors, namely CD14 and TLR4, 
were not identified in this study.  This may be due to possible detection limits for 
this novel method, or it could indicate that previously described receptors may 
have been falsely identified. The identification of the HSP70 isoform BiP is of 
particular interest as HSP70 has been proposed to act synergistically with HSP60, 
which would make it a likely candidate receptor (Alard et al., 2009).  
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1.5.7 HSP60 and Disease 
1.5.7.1 HSP60 and T2D 
Extracellular levels of HSP60 have been found to be elevated in individuals with 
diabetes when compared to controls. Aguilar-Zavala and colleagues (2008) 
screened blood samples of two groups of patients (n=151) who had been 
diagnosed with T2D less than a year or greater than 5 years before the study 
commenced for HSP60, TNFα and other markers of chronic disease.  They found 
that HSP60 associated negatively with years since diagnosis and positively with 
glucose levels.  This would indicate that HSP60 may be a molecular marker for 
the pathogenesis of early phase T2D.  This is similar to the finding that HSP60 is 
also associated with the early stages of CVD (Pockley et al., 2000).  The elevated 
levels of extracellular HSP60 may also be explained by hyperglycaemia-induced 
tissue damage, as indicated by its positive correlation with glucose levels.  The 
decline of HSP60 in later phases of T2D may be explained by the induction of 
auto-antibodies (Hoppichler et al., 1996).  
Shamaei-Tousi and colleagues (2006) investigated plasma HSP60 levels in T1D 
and T2D patients (n=855). They found that the proportion of patients who had 
experienced CVD or a myocardial infarction had detectable levels of circulating 
HSP60 compared with those patients who had not. Again this agrees with the 
proposed hypothesis that the release of HSP60 into the circulatory system is an 
early risk factor for atherosclerosis (Pockley et al., 2000).  More recently, Yuan 
and colleagues (2011) observed that HSP60 is present at detectable levels in 
salivary secretions. They detected HSP60 in 93% of the T2D patients (n=40), 
compared to only 10% of the control patients (n=40) they sampled. This is of 
particular use and significance as this provides an easy and non-invasive way of 
measuring extracellular levels of HSP60, allowing for further study of HSP60 in 
T2D.  It could also be used as a novel tool for screening of early CVD risk (Yuan 
et al., 2011).  
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1.5.7.2 HSP60 and Obesity 
Very recently it has been observed that, like in T2D, extracellular levels of HSP60 
are elevated in obese individuals.  Märker and colleagues (2012) investigated the 
plasma concentrations of HSP60 in obese and lean individual males (n=41).  They 
found that plasma levels of HSP60 were significantly higher in the obese 
individuals, and did not differ between obese individuals with and without T2D.  
It also correlated positively with BMI, blood pressure, leptin, and insulin 
resistance.  The group also suggested that the origin of circulating HSP60 may be 
the adipose tissue, as the extracellular expression of HSP60 is increased in obese 
subjects compared to lean, as well as correlating with the increased expression of 
the adipokine leptin.  The adipocyte expressed HSP60 was observed to exert a 
pro-inflammatory autocrine/paracrine effect on adipocytes. This is of particular 
interest as it is strikingly similar to other reported effects of HSP60 on vascular 
endothelial cells.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
  
1.5.7.3 HSP60 and Atherosclerosis 
A number of studies have revealed that extracellular HSP60 exerts powerful 
immunogenic and immunomodulatory effects in several experimental models 
including arthritis, T1D, T2D, obesity and atherosclerosis (Märker et al, 2012).  
HSP60 has been shown to be present in the serum of normal individuals (Pockley 
et al., 1999), and serum HSP60 levels have been observed to correlate with the 
presence of early atherosclerosis (Pockley et al., 2000; Xu et al., 2000).  A 
number of well-known atherosclerosis risk factors, such as diabetes, smoking, 
hypertension, and hyperlipidemia, have also been identified as potent inducers of 
HSP60 expression in vascular smooth muscle cells (Liao et al, 2000).  Shear 
stress, particularly in the arterial system and especially when blood pressure is 
raised, is another factor which has been shown to induce the expression of HSP60 
in cultured human endothelial cells (Hochleitner et al., 2000).  As oxidised LDLs 
play such an important part in the development of atherosclerotic lesions, 
generating foam cells, it is of interest that human monocyte cell lines exposed to 
oxidised LDLs in vitro also induce HSP60 expression. Therefore it is likely that 
foam cells situated within the atherosclerotic plaque express HSP60. Early 
vascular inflammation also sees augmented expression of a number of cytokines 
including IL-6, VCAM-1 and MCP-1. As a result, the increased HSP60 
expression may also be explained by the oxidative stress resulting from 
leukocytes traversing the vascular endothelium (Pockley, 2002).  
As discussed in Chapter 1.5.5 extracellularly expressed HSPs are capable of 
inducing the nonspecific innate immune system and promoting the adaptive 
immune system. It is perhaps not surprising then that raised levels of anti-HSP 
antibodies have also been found to be associated with the presence and 
progression of CVDs. Levels of antibodies to human HSP60 are increased in 
peripheral vascular disease and elevated levels of mycobacterial HSP65 are also 
documented in various CVDs (Wright et al., 2000). Conjecture continues to 
surround the nature of these antibodies, particularly in regard to vascular injury 
and pathogenesis. There are two schools of thought: one being that self-HSP 
antibodies play a direct pro-inflammatory role in autoimmune disease, and the 
other that immunoregulatory T cells which can differentiate self and non-self 
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HSP60s are present and exert different outcomes according to the different HSP 
epitopes (Pockley, 2002). 
Microbial HSP60s may also be a driving force in the progression of 
atherosclerosis.  Given that they are known powerful immunogens involved in the 
pathogenesis of infectious diseases, it is likely that they are present alongside 
autologous HSP60 under atherosclerotic-driving conditions. This is supported by 
the observation that HSP60 of Chlamydial pneumoniae often co-localises with 
human HSP60 in the macrophages at the site of atherosclerotic lesions (Tsan and 
Gao, 2004; Pockley, 2002).  It has been proposed that since the bacterial HSP60 
elicits pro-inflammatory TH1 responses, the co-existing autologous HSP60 may 
be inducing regulatory T cells to stimulate B cell antibody production and shift to 
a Th2 anti-inflammatory response (Pockley, 2002).  
Figure 1.2 summarises how HSP60 is postulated to promote atherosclerosis 
(Grundtman and Wick, 2011).  
 
Figure 1.2- The role of HSP60 in atherosclerotic plaque formation (adapted from 
Grundtman and Wick, 2011). 
Arterial vascular endothelial cells are more prone to atherosclerotic lesions 
compared to venous endothelial cells as they experience a much higher 
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mechanical stress due to high arterial blood pressure and flow conditions. 
Branching points in the arterial system are subjected to the greatest stress as there 
is an increased turbulent haemodynamic shear stress at these sites, predisposing 
them for the development of atherosclerotic lesions. The classical atherosclerotic 
risk factors that stress the endothelial cells result in the expression of HSP60 and 
adhesion molecules. T cells migrate into the intima by binding to the expressed 
adhesion molecules. In the intima, cytokine production occurs. This attracts 
monocytes, causing them to infiltrate into the intima too. It is yet to be ascertained 
whether monocytes bind oxidised LDLs in the circulation or after infiltration of 
the intima.  In either case, once the monocytes reach the primary T-cell dominated 
inflammatory intima they differentiate into macrophages. Smooth muscle cells 
also infiltrate the intima from the media. Both the smooth muscle cells and the 
macrophages express scavenger receptors which allow the cells to take up 
oxidised LDLs and become foam cells. There is a subsequent imbalance of pro- 
and anti-inflammatory mediators, as well as autoantibody production which 
accelerates the disease (Grundtman and Wick, 2011).  
Given that HSP60 is known to stimulate both the innate and adaptive immune 
systems, and its high sequence homology with prokaryotic HSP60s, Grundtman 
and colleagues (2011) have proposed a theory tying a lot of the unanswered 
questions surrounding the purpose of extracellular HSP60 together, and related it 
back to atherosclerosis.  Immunity to microbial HSP60 is beneficial, acquired by 
infection or vaccination. Therefore autoimmunity to epitopes of autologous 
HSP60 is present in all humans. Intracellularly expressed HSP60 plays crucial 
cytoprotective roles, while extracellularly expressed HSP60 acts as a danger 
signal for immune reactions. Known atherosclerotic risk factors result in the 
expression of HSP60 by vascular endothelial cells. Therefore, pre-existing anti-
HSP60 antibodies may have to be ‘paid for’ by cross-reactive autoimmune attack 
on cells, such as endothelial cells exposed to atherosclerotic risk factors which 
express HSP60.  
In summary, intracellular HSP60 expression is upregulated under a number of 
cellular stresses, where it performs several cytoprotective roles. It has also been 
identified that HSP60 is not purely a mitochondrial protein, and that 
extracellularly expressed HSP60, be it surface expressed or in circulation, plays a 
number of powerful immunomodulatory functions. Human HSP60 has been 
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shown to modulate APC function in a way distinct to that of LPS.  Furthermore, 
HSP60 has been shown to be capable of binding to LPS and augmenting its signal. 
The immune-stimulatory effects of HSP60, possibly due to cross-reactivity to 
microbial HSPs, have been implicated in the development of atherosclerosis.  
Both T2D and obesity are high risk factors for the development of CVDs. 
Therefore, the presence of HSP60 in individuals with T2D and obesity is not only 
an indicator of physiological stresses, but also a marker for early stage 
atherosclerosis development. 
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1.6 Aims and Objectives 
HSP60 is known to be present on the surface of cells and in systemic circulation. 
Increases in these extracellular levels of HSP60 are known to be associated with 
mitochondrial stress, damage, or impairment. Therefore, the aim of this study was 
to develop a model system for investigating HSP60 expression at the protein level 
during conditions which lead to mitochondria impairment.  
To achieve this, a set of stressors had to be established which resulted in 
impairment of mitochondrial function without inducing necrotic cell death. The 
treatments selected were high glucose and H2O2, to simulate some of the 
physiological states associated with obesity and T2D, as these metabolic 
conditions have been found to correlate with increased extracellular HSP60 
expression. A specific mitochondrial electron transport chain inhibitor, sodium 
azide, was also used.  
To find optimal mitochondria specific cell stress conditions several assays were 
implemented. Concentrations of each of the three treatments had to be identified 
that inhibited cell growth but did not increase necrotic cell death relative to 
control cells, as determined by LDH assays. Furthermore, these known stressor 
concentrations had to inhibit mitochondrial function relative to control cells, 
inferred through mitochondrial dehydrogenase activity, as determined by MTT 
assays. Once an optimal stress concentration was identified for each treatment, it 
had to be shown that HSP60 expression was indeed induced as a result. This was 
achieved through western blotting.  
By establishing a model system for the expression of HSP60, further downstream 
effects, such as the mechanisms of translocation and secretion of extracellular 
HSP60, can be investigated. As extracellular HSP60 has been implicated in 
numerous autoimmune diseases, in particular atherosclerosis, a clear 
understanding of the mechanisms that lead to the expression of extracellular 
HSP60 may result in better treatment and prevention of these disease states. 
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2 Materials and Methods 
2.1 Cell Culture 
2.1.1 HeLa Cell Culture 
The human cervical cancer HeLa cell line was purchased from the American 
Tissue Culture Collection (ATCC) (No. CCL-2). The cells were grown in DMEM 
media (Gibco) supplemented with 10% fetal bovine serum (FBS), 1X MEM non-
essential amino acid solution (Gibco), 100X penicillin/streptomycin and 3.75mg 
of sodium bicarbonate, and filter sterilized through a 0.2μm filter syringe 
(Minisart).  Cells were grown at 37°C, 5% CO2, in a humidified incubator 
(standard incubation conditions). Cells were harvested every 7 days by the 
addition of 2mL trypsin/EDTA, followed by a short incubation period and 
mechanical attrition to suspend the cells.  8mLs of DMEM media was then added 
to neutralise remaining trypsin/EDTA.  The suspended cells were then centrifuged 
(Megafuge 1.0) at 400 rcf.  The pellet was re-suspended in pre-warmed DMEM, 
and DMEM was changed 3 days after passage.  All experiments were carried out 
using exponentially growing and near-confluent cells which had been passaged 3 
days prior to experiments. 
2.1.2 Dose Response Curves 
Dose response curves were generated for the HeLa cells over 7 day periods.  The 
cells were grown in full DMEM media in 24 well plates. Dose treatments included 
high glucose (25-125mM), H2O2 (50-250μM) and sodium azide (1-100μM). The 
media was changed after 3 days. Each day, 3 wells per dose treatment were 
counted with a haemocytometer using the trypan blue exclusion method. The 
three counts were averaged and plotted to generate a growth curve. Best fit lines 
were also generated during the time of exponential cell growth and the slope was 
taken as an indication of the rate cell growth. 
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2.2 Cytotoxicity Assays 
2.2.1     LDH Assay 
Lactate dehydrogenase (LDH) is a cytosolic enzyme that is only found 
extracellularly due to necrotic cells. The Promega CytoTox96 NonRadioactive 
Cytotoxicity Assay kit was used to determine levels of LDH present in the media. 
Following the manufacturer’s protocol, each duplicate sample was treated 
identically in a 96-well culture plate (Nunc) until the end of cell culture.  The cell 
culture period lasted 3 days to acquire cells in the exponential growth phase.  At 
the end of the culture period, 10x lysis solution was added to the maximum 
control and the cells were returned to standard incubating conditions for a further 
45 minutes. The cells were then centrifuged at 250 x g for 5 minutes at room 
temperature (RT) to pellet cell debris.  50μL of the supernatant from each well of 
the culture plate was transferred to the corresponding well of a 96-well enzymatic 
assay plate (Greiner Bio-One).  Assay substrate was reconstituted by warming 
both the substrate vial and buffer to RT, and then 12mL of buffer was added to 
dissolve the substrate.  The reconstituted substrate remained at RT until the time 
of the assay.  50μL of reconstituted substrate was added to the supernatant in each 
well of the assay plate.  The plate was then covered and incubated at RT, 
protected from light, for 30 minutes.  The assay was terminated by the addition of 
50μL of Stop Solution to each well of the plate.  Air bubbles were then removed 
from all wells with a needle and the absorbance was read at 490nm using a Model 
680 Microplate Reader (Bio-Rad).  
To obtain the percentage of LDH content relative to the maximum control, the 
data was first averaged and then subtracted with the averaged media blank reading. 
The maximum control was multiplied by 1.1 to account for the dilution factor due 
to the addition of the lysis solution.  The sample recording were normalised to the 
maximum control using Equation 2.1.  The final data is presented as a percentage 
and can be interpreted as the percentage of dead cells present in the original cell 
culture, assuming all cells released an equal amount of LDH.   
 
 
Equation 2.1 – Calculating relative cytotoxicity. 
% Cytotoxicity = Experimental LDH release (OD490)                                                 
Experimental LDH release (OD490) 
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2.2.2 MTT Assay 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] is a 
tetrazolium dye.  When MTT is reduced by cellular dehydrogenases, it forms blue 
crystals intracellularly. The crystals can then be dissolved and quantified using 
spectrometry, and is indicative of mitochondrial dehydrogenase activity. The 
Sigma MTT Based In vitro Toxicology Assay Kit was used as per the 
manufacturer’s protocol. MTT was dissolved in DMEM at a concentration of 
5mg/mL and pre-warmed to 37°C.  Each duplicate sample was treated identically 
in a 96-well culture plate (Nunc) until the end of cell culture, again 3 days to 
acquire cells in the exponential growth phase, at which time the media was 
removed and replaced with reconstituted MTT in an amount equal to 10% of the 
culture medium volume. The plate was then incubated at standard incubation 
conditions for 2 hours.  After the incubation period, the culture fluid was removed 
and disposed, followed by the addition of MTT Solubilisation Solution in an 
amount equal to the original culture medium volume.  The plate was then placed 
on a minishaker for 10 minutes to assist in dissolving the crystals.  Air bubbles 
were removed from all wells with a needle and the absorbance was read at 570nm 
and the background read at 655nm using a Model 680 Microplate Reader (Bio-
Rad).  After subtracting the averaged 655nm reading from the averaged 570nm 
reading, the averaged blank was also subtracted, as per Equation 2.2. 
  
Equation 2.2 – Calculating corrected MTT absorbance. 
Experimental values were then normalised to the control and expressed as a 
percentage of mitochondrial dehydrogenase activity (Equation 2.3), since 
dehydrogenases are predominantly situated in the mitochondria. 
 
 
Equation 2.3 – Calculating mitochondrial dehydrogenase activity. 
 
Absorbance (corrected) = (Sample OD570-655nm) – (Blank OD570-655nm) 
Dehydrogenase activity (%) = 100% x Experimental sample absorbance (corrected)        
Control sample absorbance (corrected) 
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2.2.3 DCFDA Assay 
DCFDA (2,7-dichlorofluorescein diacetate) is a fluorogenic dye that measures 
hydroxyl, peroxyl and other ROS activity within cells.  It is a reagent capable of 
permeating cells, and after which, is deacetylated by cellular esterases to a non-
fluorescent compound which is incapable of diffusing back out of the cell.  It is 
later oxidized by ROS into the highly fluorescent 2, 7-dichlorofluorescin (DCF).  
Each duplicate sample was treated identically in a 96-well black culture plate 
(Greiner Bio One) until the end of the cell culture, either after 24 hours, 3 days or 
7 days.  Media was replaced after 3 days.  At the end of the culture period, the 
DMEM media was removed and the cells were washed twice with pre-warmed 
PBS.  The cells were then incubated for a further hour in Opti-MEM containing 
only 2% FBS and further supplemented with 10μM DCFDA.  After the one hour 
incubation period, the media was again removed and the cells washed twice with 
PBS.  Opti-MEM containing 2% FBS was added and the plate was left to stand at 
RT.  10μM H2O2 was added to each well immediately before reading the 
fluorescence intensity over a 30 minute period using a Fluostar Optima plate 
reader (BMG Labtechnologies) at excitation and emission wavelengths of 485nm 
and 520nm respectively. Data was standardised to the control analysis done in the 
absence of H2O2, and then expressed as relative fluorescence units to the control, 
as in Equation 2.4. 
 
 
Equation 2.4 – Calculating relative ROS activity. 
 
 
 
 
 
 
 
ROS activity (%) = 100% x (Experimental sample fluorescence/No H2O2 fuorescence)       
(Control sample fluorescence/ No H2O2 fuorescence)  
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2.3 Quantification of HSP60 Expression 
2.3.1 Protein Extraction 
Total protein was isolated using TENT buffer containing 250mM NaCl, 50mM 
Tris (pH 7.5), 5 mM EDTA (pH 8.0), 1% Triton X-100, and freshly added 0.4mM 
phenylmethylsulfonyl fluoride (PMSF) as a protease inhibitor.  HeLa cells treated 
with hydrogen peroxide (200μM), glucose (100μM), and a control sample grown 
over 3 and 7 days were treated with trypsin/EDTA and then pelleted at 400 rcf for 
5 minutes.  Samples were ruptured with 100μL TENT buffer by vortexing, and 
were subsequently incubated at 4°C for 30 minutes.  After this incubation period, 
samples were spun at 10,000 rcf for 5 minutes at 4°C to pellet cell debris. The 
supernatant was transferred to a new tube and stored at -20°C.  
2.3.2 Protein Estimation 
Protein concentration was estimated using the BCA Protein Assay kit (Pierce) 
following the manufacturers protocol. A working reagent (WR) was prepared 
constituting of 50 parts of reagent A with 1 part of reagent B.  A standard curve 
comprised of known concentrations of serially diluted bovine serum albumin 
(BSA) (Pierce) in tris buffered saline (TBS) was assayed along with samples of 
unknown concentrations and a blank containing only TBS.  25μL of each sample 
standard and unknown was transferred to a 96 well plate in triplicate followed by 
the addition of 200μL WR to each well. The plate was then mixed briefly on a 
minishaker for 30 seconds before incubating at 37°C for 30 minutes. The plate 
was then read at 570nm using the Microplate Reader and the concentration of 
sample calculated from the standard curve.  
2.3.3 Protein Separation and Transfer 
Gel Preparation 
Total protein was separated on a discontinuous gel (0.76mm).  The 10% resolving 
polyacrylamide gel was prepared by adding 4.1mL distilled water, 3.3mL 
acrylamide-bis stock (Bio-Rad), 2.5mL 1.5M Tris (pH 8.8), and 100μL 10% SDS. 
Directly before casting, 50μL of freshly prepared 10% ammonium persulphate 
(APS) (Bio-Rad) and 10 μL TEMED (Bio-Rad) were added to the mixture in a 
fume hood, and the mixture was inserted between the plates.  A layer of 70% 
ethanol was then gently overlaid.  The resolving gel was left to set for 30 minutes. 
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The stacking gel was prepared by adding 6.1mL distilled water, 1.3mL 
acrylamide-bis stock (Bio-Rad), 2.5mL 0.5M Tris (pH 6.8), and 100μL 10% SDS. 
Again, immediately before casting, 50μL of 10% APS and 10 μL TEMED were 
added to the mixture in a fume hood.  The mixture was cast on top of the 
resolving gel and the comb was gently inserted.  The stacking gel was left to set 
for a further 30 minutes.  The gel was then assembled in a Mini-Protean 3 Cell gel 
tank (Bio-Rad) buffered with 1X electrode buffer.  
Sample Preparation 
Each sample containing 20μg total protein was made up to 20μL with protein 
loading buffer.  The samples were denatured in boiling water for approximately 5 
minutes before loading into the wells.  2μL of protein Kaleidoscope ladder (Bio-
Rad) was also added alongside the samples. The gel was electrophoresed at a 
constant 20mA as the bands ran through the stacking gel, and 30mA through the 
resolving gel.  The end point was determined as when the loading dye ran off the 
gel.  
Semi-Dry Transfer 
Semi-dry transfer was completed using a 3-buffer system containing cathode, 
anode I and anode II buffers. The polyacrylamide gel was removed from the 
plates and cut to an appropriate size before being left to equilibrate in cathode 
buffer for 10 minutes. A sheet of PVDF membrane (Millipore) was cut to the 
same size as the gel.  It was then wet with methanol for approximately 15 seconds 
before being allowed to soak in distilled water for 2 minutes.  It was then left to 
equilibrate in anode buffer II for 10 minutes.  Six pieces of extra thick filter paper 
(Bio-Rad) were cut to a size marginally bigger than the membrane.  3 pieces were 
soaked in cathode buffer, 2 in anode buffer I, and 1 in anode buffer II, all for 10 
minutes before the transfer sandwich was compiled, as in Figure 2.1.  Air bubbles 
were removed by rolling a falcon tube over the top of the stack.  The cathode plate 
and safety plate were then replaced on top of the transfer sandwich, and the 
transfer cell (Bio-Rad) was run at 15V for 35 minutes. 
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Figure 2.1 –Assembly of a semi-dry transfer sandwich (image adapted from Millipore 
Immobilon-P user guide). 
After the transfer was complete, the membrane was briefly rinsed in distilled 
water before being stained with Ponceau S for 15 seconds to ascertain whether 
efficient transfer had occurred.  The stain was then washed out with distilled water. 
2.3.4 Western Blotting 
The membrane was blocked in 10% skim milk in TBST overnight at 4°C. The 
following day, the membrane was washed 6 times for 5 minutes in TBST on a 
gyro rocker (Stuart).  The membrane was then incubated in the primary polyclonal 
rabbit HSP60, HSP70 or actin antibody (Sapphire Bioscience) 1: 250 in 5% skim 
milk in TBST overnight at 4° in a humidified chamber.  After a further 6 X 5 
minute washes in TBST on a gyro rocker, the membrane was incubated in 
peroxidase conjugated goat anti-rabbit IgG (Sigma) 1:1000 in 5% skim milk in 
TBST for 5 hours in a humidified chamber on a gyro rocker.  After a further 6 X 5 
minute washes in TBST on a gyro rocker, the membrane was transferred onto a 
glass plate and incubated for 1 minute with SuperSignal West Pico 
Chemiluminescent Substrate (Pierce).  It was then covered with a plastic sheet. 
The membrane was visualised using the LAS-100 Plus Gel Documentation 
System (Fujifilm), and the intensity of the bands was measured using Gel Quant 
software.  The generated values represented the intensity of the band of the 
protein of interest less the background intensity per square millimetre.  The Quant 
values generated for the proteins of interest were normalised to the house keeper 
gene actin after probing the same membrane with the anti-actin antibody.   
After visualising, membranes were stripped for re-probing. Membranes were 
covered in membrane stripping buffer and incubated at room temperature for 10 
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minutes on a gyro rocker.  The buffer was discarded and the membranes were 
again incubated for 10 minutes in fresh stripping buffer.  They were then washed 
twice for 10 minutes in PBS, and then twice for 5 minutes in TBST, at which 
point the membranes were ready for blocking.  
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2.4 Media, Reagents & Common Solutions Preparation 
 
Name Composition 
Full HeLa media  
 
2mL penicillin/streptomycin (100X). 
2.5mL sodium bicarbonate 1.5g/100mL. 
1mL MEM non-essential amino acids (100X). 
10mL FBS. 
Bring volume to 100mL with DMEM medium then 
filter through a 0.2μm filter. Store at 4˚C. 
Phosphate buffered 
saline (PBS) 
8g NaCl (137mM). 
0.2g KCl (2.7mM). 
1.44g Na2HPO4 (4.0mM). 
0.24g KH2PO4 (1.7mM). 
Dissolve in 800mL ddH2O and adjust to pH 7, bring to 
1L. 
1.5M Tris-HCl pH 8.8 45.42g Tris. 
Dissolve in 200 mL ddH2O, adjust to pH 8.8 and bring 
to 250mL. 
0.5M Tris-HCl pH 6.8 15.14g Tris. 
Dissolve in 200mL ddH2O, adjust to pH 6.8 and bring 
to 250mL. 
10% SDS 5g SDS 
Make up to 50mL with ddH2O water. 
5x Electrode buffer 15g Tris (124mM). 
72g glycine (959mM). 
50 mL of 10% SDS (0.5%). 
Make up to 1L with ddH2O. 
Protein loading buffer 3mL 10% SDS. 
1mL 1M Tris pH6.8. 
0.2mL 2% bromophenol blue. 
4mL glycerol. 
0.8mL ddH2O. 
Mix well and store in 1mL aliquots at -20˚C. 
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Commassie Blue stain 0.5g Brilliant Blue R-250 (0.1%) 
Dissolve in 500mL of fixative/destain and filter through 
filter paper. 
Gel fixative/destain 400mL methanol (40%). 
100mL acetic acid (10%). 
500mL of ddH2O. 
Cathode buffer 0.303g Tris 
0.3g glycine 
10mL methanol 
Dissolve in 80mL ddH2O, adjust to pH 9.4 and bring to 
100mL. 
Anode buffer I 3.63g Tris. 
10mL methanol. 
Dissolve in 80mL ddH2O, adjust to pH 10.4 and bring 
to 100mL. 
Anode buffer II 0.303g Tris. 
10mL methanol. 
Dissolve in 80mL ddH2O, adjust to pH 10.4 and bring 
to 100mL. 
Membrane stripping 
buffer 
15g glycine. 
1g SDS. 
10mL Tween20. 
Dissolve in 800mL ddH2O, adjust to pH 2.2 and bring 
to 1L. 
10x Tris buffered saline 
(TBS) 
12.10g Tris (0.1M). 
87.66g NaCl (1.5M). 
Dissolve in 800mL ddH2O, adjust to pH 7.7 and bring 
to 1L. 
Ponceau S. Add in the order: 
10mL MQ water. 
0.3mL glacial acetic acid. 
33mg Ponceau S. 
Bring to 30mL with MQ water and store at RT. 
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TBS-Tween (TBST) 100mL 10x TBS. 
0.5mL Tween20 (0.05%). 
Make up to 1 L with ddH2O. 
TENT buffer 1.51g Tris (50 mM). 
10.96g NaCl (150 mM). 
0.37g EDTA (5 mM). 
0.75 mL TritonX-100 (0.25%). 
Dissolve in 200 mL ddH2O, adjust to pH 7.4 and bring 
to 250mL. Supplement with 0.4 mM 
phenylmethylsulfonyl fluoride fresh. 
400μM DCFDA 2.12mg DCFDA. 
Dissolve in 10ml dimethyl sulphoxide (DMSO).  
Opti-MEM media 1mL penicillin/streptomycin (5000X). 
1.25mL sodium bicarbonate 1.5g/100mL. 
0.5mL MEM non-essential amino acids (100X). 
1mL FBS. 
Bring volume to 50mL with OptiMEM medium then 
filter through a 0.2μm filter. Store at 4˚C. 
1M Glucose 1.80g Glucose. 
Dissolve in 10mL dd ddH2O. 
1mM Sodium azide 1.30mg Sodium Azide. 
Dissolve in 20mL ddH2O. 
1M H2O2 1mL H2O2 (27%). 
Add to 6.97mL ddH2O. 
1mM H2O2 10μL 1M H2O2. 
Add to 10mL ddH2O. 
HeLa media absent of 
glucose 
2mL penicillin/streptomycin (100X). 
2.5mL sodium bicarbonate 1.5g/100mL. 
1mL MEM non-essential amino acids (100X). 
11mg Sodium pyruvate. 
10mL FBS. 
Bring volume to 100mL with DMEM medium 
containing no glucose, then filter through a 0.2μm filter. 
Store at 4˚C. 
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2.5 Statistical Analysis 
All statistical analysis in this study was carried out using Microsoft Excel.  Data 
was averaged where appropriate, and the standard error of the mean (S.E.M.) was 
calculated using Equation 2.5 in Excel. 
 
Equation 2.5 – Calculating standard error of the mean in Excel. 
A two-tailed student’s t-test was carried out to determine the significance of the 
data.  The accepted level of significance was p < 0.05, which was denoted as ‘*’. 
 
 
 
S.E.M. = STDEV (A1:A2) / SQRT (COUNT (A1:A2)) 
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3 Effects of Glucose, H2O2 and Sodium Azide on HeLa 
Cell Growth 
3.1 Introduction 
T2D and obesity are disease states which are both associated with chronic, low-
level, systemic inflammation as well as elevated levels of circulating HSP60. 
Therefore these patients are at a high risk of developing CVDs. Both 
hyperglycaemia and increased oxidative stress have also been associated with 
these disorders, as well as being linked to mitochondrial dysfunction (Chapters 
1.2.3 and 1.3.3).  The cytotoxic effects of H2O2 on HeLa cells have been 
previously documented (Singh et al., 2007; Nakamura et al., 2003), however the 
majority of evidence of glucose cytotoxicity pertains to the human pancreatic β 
islet cells (Robertson et al., 2003) and tissues where glucose can passively enter.  
Using HeLa cells allows for the development of a peripheral tissue model, and by 
using high glucose and H2O2, the treatments reflect two of the most pertinent T2D 
and obesity conditions.  
In addition, a known mitochondrial inhibitor was also used in these experiments. 
Sodium azide is a highly toxic inorganic compound which inhibits complex IV of 
the mitochondrial electron transport chain.  It achieves this due to the azide anion 
binding irreversibly to the heme cofactor of cytochrome c oxidase, a process 
similar to the action of carbon monoxide (Kaal et al., 2000; Varming et al., 1996). 
Sodium azide has an LD50 of 27 mg/kg when administered orally to rats, 
compared to potassium cyanide which has an LD50 of 5 mg/kg.  In humans, lethal 
doses have been reported for exposure greater than 10mg/kg, while nonlethal 
doses have been reported for exposures less than 2 mg/kg (Chang and Lamm, 
2003). 
Other researchers have used various concentrations of these three compounds in 
cell cultures but due to the differences in the cell type, the constant changes to the 
culture population through clonal selection of cells through each passage, as well 
as the nature of further experiments, the first task of this project was to test the 
inhibitory effects on cell growth of glucose, H2O2, and sodium azide on HeLa 
cells.  This was done at a number of different glucose (25-125mM), H2O2 (0-
250μM), and sodium azide (0-100μM) concentrations to generate dose response 
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growth curves by monitoring cell growth every 24 hours by trypan blue exclusion 
assay.  The slopes of the curves through the exponential growth phase were also 
used to provide an indication of growth rate.   
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3.2 Methods 
3.2.1 Cell Culture and Dose Response Curves 
Stock solutions of 1M glucose, 1mM H2O2 and 1mM sodium azide were prepared 
in ddH2O as in Chapter 2.4. HeLa cells were seeded at a density of 
approximately 60,000 cells/mL onto a 24 hour plate containing 1mL glucose-free  
HeLa media which was supplemented with 25, 50, 75, 100, 125mM glucose in 
triplicate.  Cells were also seeded at a density of approximately 60,000 cells/mL 
onto 24 hour plates containing 1mL full HeLa media with added 0, 50, 100, 150, 
200, 250mM H2O2 and 0, 1, 10, 25, 50, 100mM sodium azide, again in triplicate. 
The plates were then placed back into standard incubation conditions. Cell density 
was estimated by the trypan blue exclusion method every 24 hours. 
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3.3 Results 
3.3.1 Dose Response for Glucose Treatment 
Cells treated with 50 and 75mM glucose showed a slightly reduced growth rate 
compared with the control, while the 100 and 125mM groups had considerably 
reduced growth rate through to the end of the culture period, shown in Figure 3.1.  
 
Figure 3.1- Cell growth in glucose (mM). Error bars showing S.E.M. 
 
To compare cell growth across treatments, the number of cells at each time point 
was normalised to the number of control cells. The rate of cell growth was 
determined during the exponential growth phase between days 3 and 5 of the 
culture period. The slopes were taken from the graph over this time period, as 
shown in Figure 3.2. The gradient of the lines of best fit are expressed in Table 
3.1. The degree of growth rate inhibition was then determined, as shown in 
Figure 3.3.  
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Figure 3.2- Cell growth in glucose with lines of best fit. 
 
 
 
 
 
Table 3.1- Gradients of lines of best fit from Figure 3.2 relative to control. 
 
Figure 3.3- Rates of growth inhibition relative to control in glucose. 
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3.3.2 Dose Response for H2O2 Treatment 
As shown in Figure 3.4, Cells treated with 50, 100 and 150μM H2O2 showed 
growth rates comparable, if not greater than, with the control, while the 200 and 
250μM groups had considerably reduced growth rate through to the end of the 
culture period.  
 
Figure 3.4- Cell growth in H2O2 (μM). Error bars showing S.E.M. 
 
To compare cell growth across treatments, the number of cells at each time point 
was normalised to the number of control cells. The rate of cell growth was 
determined during the exponential growth phase between days 3 and 5 of the 
culture period. The slopes were taken from the graph over this time period, as 
shown in Figure 3.5. The gradient of the lines of best fit are expressed in Table 
3.2. The degree of growth rate inhibition was then determined, as shown in 
Figure 3.6.  
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Figure 3.5- Cell growth in H2O2 with lines of best fit.  
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Figure 3.6- Rates of growth inhibition relative to control in H2O2.  
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3.3.3 Dose Response for Sodium Azide Treatment 
Cells treated with 1, 10 and 25μM sodium azide showed growth rates comparable, 
if not greater than, with the control. The 200 and 250μM groups had considerably 
reduced growth rate through to the end of the culture period compared to the 
control, as shown in Figure 3.4 
 
Figure 3.7- Cell growth in sodium azide (μM). Error bars showing S.E.M. 
 
To compare cell growth across treatments, the number of cells at each time point 
was normalised to the number of control cells. The rate of cell growth was 
determined during the exponential growth phase between days 3 and 5 of the 
culture period. The slopes were taken from the graph over this time period, as 
shown in Figure 3.8. The gradient of the lines of best fit are expressed in Table 
3.3. The degree of growth rate inhibition was then determined, as shown in 
Figure 3.9.  
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Figure 3.8- Cell growth in sodium azide with lines of best fit. 
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Table 3.3- Gradients of lines of best fit from Figure 3.8 relative to control. 
 
Figure 3.9- Rates of growth inhibition relative to control in sodium azide.  
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3.4 Discussion 
The objective of this section of the study was to assess the inhibitory effects on 
cell growth of glucose, H2O2 and sodium azide on HeLa cells through dose 
response experiments. In this experiment, HeLa cells were incubated with a wide 
range of glucose, H2O2 and sodium azide concentrations, with varying inhibitory 
effects on growth rate.  
As was to be expected, increasing the concentration of the treatment resulted in 
increased inhibition of cell growth. Slight growth inhibition resulted from 
treatments of 50 and 75mM glucose (11% and 30% inhibition respectively), 
150μM H2O2 (4%), and 10 and 25μM sodium azide (11% and 9% respectively). 
Strong growth inhibition resulted from treatments of 100 and 125mM glucose (36% 
and 84% respectively), 200 and 250μM H2O2 (54% and 91% respectively), and 50 
and 100μM sodium azide (47% and 78% respectively). 
The inhibition of growth of human cells due to high glucose has previously been 
reported in numerous studies, where it has been postulated to be caused by 
impairment of the transforming growth factor-β 1 (TGF-β 1) signal pathway  
(Mather et al., 2009; Samikannu et al., 2006). TGF-β 1 is a secreted protein that 
performs functions involved in the control of cell growth, proliferation, 
differentiation and apoptosis. High glucose interferes with the TGF-β 1 signal 
pathway by inhibition of the mevalonate pathway. Downstream effects of this 
inhibitory effect are increased TGF-β 1 secretion and the inhibition of Ras 
prenylation, ultimately reducing cellular proliferation (Mather et al., 2009). Cell 
growth reportedly drastically declines after achieving 50mM glucose, which 
agrees with these results. However, most previous studies find a significant 
decline in cell growth with concentrations as low as 25mM, which was not seen in 
this study. In fact the glucose concentration of the stock media is 25mM. This 
may be explained by the differences in cell type used across studies, as HeLa cells 
are considered to be a remarkably hardy and robust cell type (Capes-Davis et al., 
2010). It may also be explained by the constantly evolving nature of cell lines in 
culture. Through serial passage, the properties of the cell line change over time. A 
wide range of alterations to the behaviour and function of cells, including cell 
morphology, growth rates, protein expression and cell signalling have been 
reported (ATCC, 2007). While it is unlikely that this impacted on the final results 
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of these experiments, the potential still exists and is worth considering when 
evaluating all experiments that utilise cell culture.   
H2O2 has been commonly used to inhibit many micro-organisms, but particularly 
as an anti-bacterial, due to its property of inhibiting growth (Halliwell et al., 2000). 
In human cell lines, H2O2 has also been reported to inhibit cell proliferation, 
which agrees with these results. It has been reported that sub-lethal doses of H2O2 
result in a dose dependent inhibition of DNA synthesis, resulting in a cumulative 
and irreversible loss of replicative ability. As a result, doubling time increases and 
cells enter cellular arrest, undertaking a senescent-like state (Chen and Ames, 
1994). High concentrations of H2O2 have also been reported to induce apoptosis 
through mitochondrial pathways in HeLa cells (Singh et al., 2007).  
As an inhibitor of the mitochondrial electron transport chain, sodium azide has 
long been known to inhibit cell growth. It has been used as a biocide for decades 
due to its bacteriostatic properties (Lichstein and Seoule, 1943). As mentioned 
previously, in human cells, sodium azide is acutely toxic. Therefore, it is perhaps 
not surprising that at the micro molar concentrations used in these dose response 
experiments, sodium azide exhibits the same inhibitory effect on cell growth as 
seen in micro-organisms.  
It is interesting that a degree of hormesis was present in all treatments. Hormesis 
is the name given to the stimulatory effects caused by low levels of potentially 
toxic agents (Calabrese et al., 2012). The 25mM glucose, and 50 and 100μM 
H2O2 treatments all resulted in increased growth rates compared to the control 
over the exponential growth phase. The 1μM sodium azide was found to have a 
comparable growth rate to the control. While it may not be surprising that the 
comparatively low glucose levels result in increased growth, as it would convey a 
greater energy source to the cell culture, it is of interest that H2O2 does increase 
growth, which agrees with results of previous studies (Burdon, 1995). H2O2 and 
its stimulatory effect on cell proliferation have been of particular interest as it has 
been identified that the elevated levels of H2O2 that result from regular exercise 
have a hormetic effect, indicating that minor oxidative stress may have a 
beneficial effect (Radak et al., 2008). 
It should also be noted that after a few days the colour of media became yellow as 
treatment concentration increased. This is most likely due to the build-up of lactic 
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acid during glycolysis, indicating that growth inhibition is perhaps a result of 
mitochondrial inhibition. It can also be explained through lactate build-up, as it is 
known to reduce the rate of cell growth. Under the inhibitory effects of the higher 
treatment concentrations, cells accelerate glycolysis to compensate for reduced 
ATP production via oxidative phosphorylation. The reduction of pyruvate to 
lactate provides a means of re-oxidising excess NADH generated during 
glycolysis. This resulting lactate accumulation from glycolysis normally serves as 
the substrate for gluconeogenesis in the liver. Therefore, in this cell culture system, 
lactate could not be completely oxidized leading to a build-up in the culture media. 
Additionally, accelerated glycolysis at high treatment concentrations could lead to 
a faster turnover rate for glucose. Therefore substrate depletion is another factor to 
be considered (Lao and Toth, 2008). 
To confirm that the impaired cell growth from this chapter was a result of 
mitochondrial inhibition, and not necrotic cell death, biochemical assays were 
utilised as described in Chapter 4.  
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4 Effects of Glucose, H2O2 and Sodium Azide on HeLa 
Cell Function 
4.1 Introduction 
The use of biochemical assays provides crucial insight as to the intracellularly 
functioning of cells. To further assess the growth inhibitory effects of glucose, 
H2O2 and sodium azide on HeLa cells LDH, MTT and DCFDA assays were 
utilised. LDH assays were used to determine if the cytotoxicity of the three 
treatments was due to cell lysis, representative of necrotic cell death (Decker and 
Lohmann-Matthes, 1988).  MTT assays were undertaken to indirectly measure 
mitochondrial dehydrogenase activity (Marshall et al., 1995).  Finally, DCFDA 
assays were carried out to quantify cellular oxidative stress (Wang and Joseph, 
1999). 
4.2 Methods 
4.2.1 LDH Assay 
Lactate dehydrogenase is a strictly cytosolic enzyme which will only be released 
into the surrounding media after necrotic cell death.  
Near confluent HeLa cells were seeded onto a 96-well plate in 100μL of DMEM. 
8 wells were treated with glucose (25-125mM), H2O2 (0-250μM), and sodium 
azide (0-100μM). The plate was then returned to incubate in standard incubation 
conditions for 3 days, when the cells would be in the exponential growth phase. 
After the 72 hours, samples were prepared as in Chapter 2.2.1. Briefly, one set of 
control cells (maximum control) was treated with 100μL 10x lysis solution and 
the plate was returned to standard incubating conditions for 45 minutes. After this 
time period, the plate was centrifuged at 250xg for 5 minutes at RT to pellet cell 
debris. 50μL of the supernatant from each well of the culture plate was transferred 
to the corresponding well of a 96-well enzymatic assay plate. 50μL of 
reconstituted substrate was then added to the supernatant in each well of the assay 
plate. The plate was then covered from light and incubated at RT for 30 minutes. 
The assay was terminated by the addition of 50μL of Stop Solution to each well of 
the plate. Air bubbles were removed from all wells with a needle and the 
absorbance was read at 490nm. The data were calculated according to Equation 
2.1 and presented as a percentage of the corresponding maximum control. 
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4.2.2 MTT Assay 
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay 
is commonly accepted as a measure of cell viability. It is based on the activity of 
intracellular oxidoreductase enzymes. Of which NADH is primarily responsible 
for most MTT reduction (Berridge et al., 2005). As most oxidoreductases are 
located in the mitochondrial electron transport system, the MTT assay is also able 
to be used as an indirect measure of mitochondrial dehydrogenase activity. 
Near confluent HeLa cells were seeded onto a 96-well plate in 100μL of DMEM. 
8 wells were treated with glucose (25-125mM), H2O2 (0-250μM), and sodium 
azide (0-100μM). The plate was then returned to incubate in standard incubation 
conditions for 3 days, when the cells would be in the exponential growth phase. 
After the 72 hours, samples were prepared as in Chapter 2.2.2. Briefly, after the 
72 hours the media was removed and replaced with 10μL reconstituted MTT in 
DMEM. The plate was then incubated at standard incubation conditions for 2 
hours. After the incubation period, the culture fluid was removed and disposed of. 
This was followed by the addition of 100μL MTT Solubilisation Solution. The 
plate was then placed on a minishaker for 10 minutes to assist in dissolving the 
crystals. Air bubbles were then removed from all wells with a needle and the 
absorbance was read at 570nm and the background read at 655nm. After 
subtracting the averaged 655nm reading from the averaged 570nm reading, the 
averaged blank was also subtracted, as per Equation 2.2. Experimental values 
were then normalised to the control and expressed as a percentage of 
mitochondrial dehydrogenase activity (Equation 2.3), since dehydrogenases are 
predominantly situated in the mitochondria. 
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4.2.3 DCFDA Assay 
DCFDA (2,7-dichlorofluorescein diacetate) is a fluorogenic dye that measures 
hydroxyl, peroxyl and other ROS activity within cells. It is a reagent capable of 
permeating cells, and after which, is deacetylated by cellular esterases to a non-
fluorescent compound which is incapable of diffusing back out of the cell. It is 
later oxidized by ROS into the highly fluorescent 2, 7-dichlorofluorescin (DCF). 
Near confluent HeLa cells were seeded onto a 96-well black culture plate in 
100μL of DMEM. 8 wells were treated with glucose (25-125mM), H2O2 (0-
250μM), and sodium azide (0-100μM). The plate was then returned to incubate in 
standard incubation conditions for time periods of 24 hours, 3 days, and 7 days. 
Plates incubated for 7 days had their media replaced after 3 days. At the end of the 
incubation period, the DMEM media was removed and the cells were washed 
twice with 100μL pre-warmed PBS. The cells were then incubated for a further 
hour in 100μL Opti-MEM containing only 2% FBS and further supplemented 
with 2.5μL of 400μM DCFDA. After the one hour incubation period, the media 
was again removed and the cells washed twice with 100μL PBS. 200μL Opti-
MEM was then added, containing 2% FBS, and the plate was left to stand at RT. 
10μL of 200μM H2O2 was added to each well, except the H2O2 absent control, 
immediately before reading the fluorescence intensity over a 30 minute period at 
excitation and emission wavelengths of 485nm and 520nm respectively. Data 
produced was standardised to the control absent of H2O2 and expressed relative to 
the control sample.  
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4.3 Results 
4.3.1 LDH Assays 
Lactate dehydrogenase is an intracellular enzyme that is only released into the 
media upon cell lysis, thus this assay was used to determine if the cytoxicity of 
glucose, H2O2, and sodium azide on HeLa cells at the high concentrations 
described in Chapter 3 was indeed due to necrotic cell death.  
After 3 days in culture, the percentage of LDH content relative to corresponding 
maximum control samples was calculated. It was assumed that every dead cell 
released an equal amount of LDH. Therefore the percentage of LDH content was 
interpreted as the percentage of lysed cells. 
 
The control sample had 25.50 ± 1.31% lysed cells, and was not significantly 
different from the 75 and 100mM glucose groups, which had 22.76 ± 1.29% and 
26.46 ± 1.00% of lysed cells, respectively. However, treatment with 125mM 
glucose resulted in a significantly increased (p < 0.05) percentage of lysed cells 
compared to the control; resulting in 31.46 ± 1.37% lysed cells, as shown in 
Figure 4.1. 
 
 
Figure 4.1- Percentage of lysed cells in the presence of glucose. Bar graph showing 
means ± S.E.M. * = p < 0.05. 
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The control sample had 27.84 ± 3.04% lysed cells, and was not significantly 
different from the 150 and 200μM H2O2 groups, which had 27.61 ± 2.33% and 
30.69 ± 2.19% of lysed cells, respectively. However, samples treated with 250μM 
H2O2 resulted in a significantly increased (p < 0.05) percentage of lysed cells 
compared to the control; resulting in 37.71 ± 3.09% lysed cells, as shown in 
Figure 4.2. 
 
 
Figure 4.2- Percentage of lysed cells in the presence of H2O2. Bar graph showing means 
± S.E.M. * = p < 0.05. 
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The control sample had 24.42 ± 1.13% lysed cells, and was not significantly 
different from the 25 and 50μM sodium azide groups, which had 26.80 ± 1.18% 
and 27.57 ± 1.51% of lysed cells, respectively. However, treatment with 100μM 
sodium azide resulted in a significantly increased (p < 0.05) percentage of lysed 
cells compared to the control; resulting in 32.08 ± 2.85% lysed cells, as shown in 
Figure 4.3. 
 
 
Figure 4.3- Percentage of lysed cells in the presence of sodium azide. Bar graph showing 
means ± S.E.M. * = p < 0.05. 
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4.3.2 MTT Assays 
The MTT assay is commonly accepted as a measure of cell viability, and is also 
able to indirectly measure mitochondrial dehydrogenase activity. Thus it was used 
to determine if the inhibitory cell growth effects of glucose, H2O2, and sodium 
azide on HeLa cells was due to effects on mitochondrial activity. 
After 3 days in culture, cells were incubated with MTT for 2 hours. After which 
the formazan crystals were solubilised, the absorbance read, and results were 
interpreted as a percentage of mitochondrial activity relative to the control group.  
 
All glucose samples were found to have significantly decreased (p < 0.05) 
mitochondrial dehydrogenase activity compared to control cells. 75mM glucose 
resulted in 84.29 ± 1.20%, 100mM resulted in 78.21 ± 1.13%, and 125mM 
glucose resulted in 73.96 ± 1.12% mitochondrial dehydrogenase activity, as seen 
in Figure 4.4.  
 
 
Figure 4.4- Mitochondrial dehydrogenase activity in the presence of glucose. Bar graph 
showing the mean ± S.E.M. * = p < 0.05. 
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All H2O2 samples were found to have significantly decreased (p < 0.05) 
mitochondrial dehydrogenase activity relative to control cells. 150μM H2O2 
resulted in 87.70 ± 3.07%, 200μM resulted in 81.97 ± 1.41%, and 250μM resulted 
in 59.61 ± 4.21% mitochondrial dehydrogenase activity, as shown in Figure 4.5.  
 
 
Figure 4.5- Mitochondrial dehydrogenase activity in the presence of H2O2. Bar graph 
showing the mean ± S.E.M. * = p < 0.05. 
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All sodium azide samples were found to have significantly decreased (p < 0.05) 
mitochondrial dehydrogenase activity relative to control cells. 25μM sodium azide 
resulted in 91.76 ± 2.27%, 50μM resulted in 73.61 ± 3.53%, and 100μM resulted 
in 75.33 ± 1.20% mitochondrial dehydrogenase activity, as seen in Figure 4.6.  
 
 
Figure 4.6- Mitochondrial dehydrogenase activity in the presence of sodium azide. Bar 
graph showing the mean ± S.E.M. * = p < 0.05. 
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4.3.3 DCFDA Assays 
DCFDA measures hydroxyl, peroxyl and other ROS activity within cells, thus the 
DCFDA assay was used to determine the degree of ROS generation in HeLa cells 
treated with glucose, H2O2, and sodium azide. 
After 1, 3, and 7 days in culture, cells were incubated with DCFDA for 1 hour. 
After which the fluorescence was read, and results were normalised to the H2O2 
absent control. Results were interpreted as a percentage of ROS levels relative to 
the control group. 
 
After 24 hours, all samples were found to have significantly increased (p < 0.05) 
ROS levels. The glucose treatment resulted in 109.06 ± 2.27%, the H2O2 
treatment resulted in 112.93 ± 2.71%, and the sodium azide treatment resulted in 
110.77 ± 2.24% ROS levels, as shown in Figure 4.7.  
 
 
Figure 4.7- ROS levels in the presence of glucose, H2O2, and sodium azide over 24 hours. 
Bar graph showing the mean ± S.E.M. * = p < 0.05. 
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After 3 days, all samples were found to have significantly increased (p < 0.05) 
ROS levels. The glucose treatment resulted in 123.63 ± 6.24%, the H2O2 
treatment resulted in 135.36 ± 7.33%, and the sodium azide treatment resulted in 
134.77 ± 7.15% ROS levels, as seen in Figure 4.8.  
 
 
Figure 4.8- ROS levels in the presence of glucose, H2O2, and sodium azide over 3 days. 
Bar graph showing the mean ± S.E.M. * = p < 0.05. 
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After 7 days, all samples were found to have significantly increased (p < 0.05) 
ROS levels. The glucose treatment resulted in 179.95 ± 23.78%, the H2O2 
treatment resulted in 304.56 ± 29.02%, and the sodium azide treatment resulted in 
279.13 ± 43.82% ROS levels, as shown in Figure 4.9.  
 
 
Figure 4.9- ROS levels in the presence of glucose, H2O2, and sodium azide over 7 days. 
Bar graph showing the mean ± S.E.M. * = p < 0.05. 
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4.4 Discussion 
The objective of this portion of the study was to find a concentration of each of 
glucose, H2O2, and sodium azide which impaired mitochondrial activity but did 
not result in necrotic cell death, thus providing optimal mitochondrial stress 
conditions to investigate the mitochondria specific stress response that induces 
HSP60 expression. The concentrations of glucose, H2O2, and sodium azide used 
in these assays were only the concentrations that were deemed to result in 
significant growth inhibition as seen in Chapter 3.  
The LDH assay showed that, compared with a control sample, treatment with 75 
and 100mM glucose, 150 and 200μM H2O2, and 25 and 50μM sodium azide did 
not result in significantly increased cell lysis. Treatment with 125mM glucose, 
250μM H2O2, and 100μM sodium azide did however result in significantly 
increased (p < 0.05) cell death. The MTT assay showed that, compared with 
control, treatment with 75, 100 and 125mM glucose, 150, 200 and 250μM H2O2, 
and 25, 50, and 100μM sodium azide all resulted in significantly reduced (p < 
0.05) mitochondrial dehydrogenase activity.  
The 125mM glucose, 250μM H2O2, and 100μM sodium azide treatments all 
indicate that cell lysis occurs at these concentrations. The MTT assay also 
indicates that there is reduced mitochondrial activity at these concentrations. This 
raises the question of whether the cell lysis experienced by these cells is due to 
mitochondrial inhibition, or the other way around. From this data it is impossible 
to tell. In future, as the LDH assay is only representative of necrotic cell death, it 
would be of great benefit and interest to perform assays, such as a cytochrome c 
assay, to assess the degree of apoptosis experienced by cells exposed to these 
treatments to better explain the phenomena surrounding some of these questions 
(Guo et al., 2002).  
 
Hyperglycaemia has a number of deleterious metabolic consequences including 
creating advanced glycated end-products (AGE), altering signal transduction, 
tissue damage and abnormal gene expression, but the consequence primarily 
concerned with this study is increased oxidative stress (Diaz-Flores et al., 2004). 
There is an increase in intracellular ROS activity when cells are exposed to 
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chronic hyperglycaemia. This occurs through several mechanisms. Chronic 
hyperglycaemia results in elevated levels of glucose, resulting in the ‘Crabtree 
effect’. This was first described by Herbert Crabtree in yeast, Saccharomyces 
cerevisiae, where he observed that the presence of high concentrations of glucose 
caused glycolysis to accelerate while inhibiting oxidative phosphorylation 
(Crabtree, 1928). In pertaining to this study, an increased rate of glycolysis due to 
hyperglycaemia would result in elevated levels of glyceraldehyde-3-phosphate, an 
intermediate metabolite along the glycolysis pathway. Glyceradehyde-3-
phosphate undergoes auto-oxidation, and in doing so generates H2O2, thus 
increasing intracellular ROS activity (Robertson et al, 2003). There is also a 
hyperglycaemia associated decrease in the efficiency of reduction of molecular 
oxygen at the complex IV of the electron transport chain, increasing the amount of 
ROS generated (Zhang and Gutterman, 2007). However the mechanisms of this 
phenomenon have been poorly documented, and could well be a result of the 
aforementioned H2O2 generated by glyceraldehyde-6-phosphate auto-oxidation. 
The overproduction of mitochondrial ROS has been found to be associated with 
dynamic changes to mitochondrial morphology. Rapid fragmentation of the 
mitochondrion ensues, which has been found to be driven by the mitochondria’s 
fission machinery, a known marker of apoptosis (Yu et al, 2008).  
Hyperglycaemic conditions have been previously reported in the literature to 
induce cell death in a number of human cell lines through mitochondrial mediated 
apoptotic pathways. Reported pathways include mitochondrial fission (Yu et al, 
2008), mitochondrial release of apoptosis-inducing factor (AIF) (Santiago et al., 
2007) elevated production of ROSs (Peiro et al., 2001), and activation of proteins 
involved in apoptotic cell death including members of the caspase and Bcl-2 
families (Allen et al., 2005). Based on the glucose concentrations used in previous 
studies, the HeLa cells used in this experiment were capable of withstanding 
concentrations of glucose much higher than other cell types. For instance, 
pancreatic islet cells undergo apoptosis when exposed to 25mM glucose 
concentrations (Allen et al., 2005). However, as mentioned in the previous 
chapter, HeLa cells are renowned for their robust nature. Also the potential the 
cells used in these experiments have evolved into a more hyperglycaemic tolerant 
cell line through serial passage remains a possibility. Either could explain the 
discrepancy between the much higher glucose concentrations the HeLa can 
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tolerate. In saying that, the trend still exists where with increasing glucose 
concentration, there is greater cell death.  
High glucose concentrations also result in mitochondrial inhibition. As previously 
mentioned, high glucose levels results in increased levels of glyceraldehyde-6-
phosphate, which undergoes auto-oxidation to generate H2O2 (Robertson et al., 
2003). It has been documented that the stimulation of increased mitochondria 
derived ROS production in such a way correlates with mitochondrial inhibition, 
which a physiological state of high levels of glucose would induce (Russell et al., 
2002). A further piece of evidence linking high glucose to oxidative stress is that 
high glucose has been found to induce the upregulation of antioxidant enzymes in 
human endothelial cells (Ceriello et al., 1996). It is therefore likely that the 
mitochondrial inhibition due to high levels of glucose as seen in this experiment 
was due to increased ROS levels. This aspect was further investigated using the 
DCFDA assay discussed later in this chapter.  
 
H2O2 occurs naturally in cells as a by-product of the mitochondrial electron 
transport chain. At complex IV of the electron transport chain, molecular oxygen 
is reduced to water. However, this is not a completely efficient reaction and 1-4% 
of the oxygen is incompletely reduced to superoxide (O2
-
). As a ROS, O2
-
 is 
hazardous as it may cause oxidative damage. Superoxide dismutases (SOD), and 
specifically SOD2 in the mitochondria, act to quickly remove this threat. The 
SOD2 enzyme catalyses a reaction in which O2
-
 is converted into O2 and H2O2. 
H2O2 is further processed by the catalase enzyme located in peroxisomes adjacent 
to the mitochondria. Catalase catalyses a reaction in which H2O2 is converted into 
water and oxygen. However, these reactions are not completely efficient either, 
and their efficiency further declines when ROS generation from the electron 
transport chain increases, such as during hyperglycaemia as previously detailed. 
H2O2 is capable of leaking out of the mitochondria resulting in cellular oxidative 
stress (Han et al., 2001).  
If H2O2 is not appropriately dealt with, it is capable of causing oxidative damage. 
In the mitochondria, accumulating oxidative damage may affect the efficiency of 
the mitochondrial electron transport chain, and further increase the rate of ROS 
generation (Han et al., 2001). Oxidative damage may also occur to the DNA. Sub 
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lethal doses of H2O2 have been reported to induce oxidative DNA lesions. Such 
lesions may result in DNA strand breaks, and may also be mutagenic and 
cytotoxic (Nakamura et al., 2003). Ultimately, H2O2 has been found to induce 
apoptosis in cells through intrinsic cell death pathways. H2O2 upregulates the 
expression of the p73 protein, a member of the p53 protein family, which triggers 
apoptosis in response to DNA damaging agents. p73 in turn upregulates its 
downstream target Bax. The Bax protein inserts into the outer mitochondrial 
membrane to form an oligomeric pore. This allows for the release of cytochrome c 
from the mitochondria into the cytoplasm where it binds with apoptotic protease 
activating factor-1 (APAF-1) to form an apoptosome. The apoptosome activates 
caspases-9 and -3 to begin a chain reaction of intracellular protein degradation 
culminating in a process of controlled cell death (Singh et al., 2007; Wolter et al., 
1997).  
H2O2 has already been reported to induce cell death in human cells. As previously 
mentioned, high concentrations of H2O2 have been reported to activate 
mitochondrial mediated apoptosis pathways in HeLa cells (Singh et al, 2007). 
However, the concentration used to achieve apoptosis in that study was only 
125μM, whereas increased cell death in this study was only achieved from 250μM, 
double the concentration. Like with the glucose, this could potentially be 
explained by the evolution of a more robust and H2O2 tolerant cell line resulting 
from serial passage, although it is not possible to verify. However, a dose 
dependent trend was still observed, where increasing H2O2 concentration resulted 
in increased cell death. As has been previously mentioned, oxidative stress can 
result in mitochondrial inhibition as determined by the MTT assay (Zeevlak et al., 
2005). This effect was directly simulated by the addition of H2O2. It resulted in 
the observation of a dose dependent decrease in mitochondrial dehydrogenase 
activity as expected.  
 
Sodium azide is a known acutely toxic compound, inhibiting the electron transport 
chain by irreversibly binding to the heme cofactor of complex IV. Inhibition of 
the mitochondrial electron transport chain, at various points, is documented to 
increase mitochondrial ROS generation (Quillet-Mary et al., 1997). As a result, 
oxidative stress ensues culminating in a molecular stress response. As previously 
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mentioned, oxidative stress activates intrinsic mitochondrial apoptotic pathways, 
ultimately resulting in increased cell death. 
The resulting cell death of HeLa cells from micro molar concentrations of sodium 
azide in a dose dependent manner, as seen in these results, agrees with other cell 
death data in the literature, although it is of interest that other human cell types 
have been found to tolerate sodium azide up to milli molar levels (Gavrieli et al., 
1992). Also as expected, sodium azide impaired mitochondrial dehydrogenase 
activity. This is undoubtedly through its ability to irreversibly bind to the heme 
cofactor complex IV, and thus block the mitochondrial electron transport chain. 
 
By taking the LDH and MTT assay data together as in Table 4.1, concentrations 
which resulted purely in mitochondrial stress were determined as concentrations 
where cell death was not significantly increased according to the LDH assay but 
mitochondrial dehydrogenase activity was significantly reduced according to the 
MTT assay. Therefore optimal stress concentrations were 75 and 100mM glucose, 
150 and 200μM H2O2, and 25 and 50μM sodium azide. To determine the optimum 
stress concentration, assay data was coupled with the growth inhibition data from 
Chapter 3, as seen in Table 4.1.  
Table 4.1- Summary of LDH assay, MTT Assay, and growth inhibition results. 
Treatment Significantly 
Increased 
Cell Death? 
Significantly Reduced 
Mitochondrial 
Dehydrogenase Activity? 
Relative 
Growth 
Rate 
75mM glucose No Yes 0.7 
100mM glucose No Yes 0.64 
125mM glucose Yes Yes 0.16 
150μM H2O2 No Yes 0.96 
200μM H2O2 No Yes 0.46 
250μM H2O2 Yes Yes 0.09 
25μM sodium azide No Yes 0.91 
50μM sodium azide No Yes 0.53 
100μM sodium azide Yes Yes 0.22 
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The concentration of each treatment which resulted in no significant increase in 
cell death, but reduced mitochondrial dehydrogenase activity, and resulted in the 
greatest growth inhibition was 100mM glucose, 200μM H2O2, and 50μM sodium 
azide. These concentrations were determined as causing cellular stress targeted at 
the level of the mitochondrion, and were hence used for the remaining 
experiments including relative ROS levels and HSP protein expression.    
 
The DCFDA assays showed that treatment of HeLa cells with the identified 
concentrations of 100mM glucose, 200μM H2O2, and 50μM sodium azide all 
result in oxidative stress, as noted by the increased levels of intracellular ROS. 
Over 24 hours of exposure to the treatments, there is a significant increase in ROS 
levels, which continues to rise drastically over both 3 and 7 day treatments, as 
seen in Figure 4.10. 200μM H2O2 has the greatest effect on ROS levels, followed 
closely by 50μM sodium azide, with 100mM glucose having the least great effect 
of the three.  
 
Figure 4.10- ROS levels in the presence of glucose, H2O2, and sodium azide over 24 
hours, 3, and 7 days. Bar graph showing the mean ± S.E.M. * = p < 0.05. 
Elevated levels of ROS activity in cells is known to be indicative of mitochondrial 
compromised cells. Within mitochondria, the primary site of ROS generation is 
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generate other ROS species, such as H2O2, through various enzymatic and 
nonenzymatic reactions. The proportion of oxygen incompletely reduced to O2
- 
increases in dysfunctional mitochondria, therefore increasing mitochondrial ROS 
generation. Physiologically, this dysfunction may result from hyperglycaemia 
and/or free fatty acid flux (Zhang and Gutterman, 2007). Hyperglycaemia may 
also result in ROS generation through increased concentrations of glyceraldehyde-
6-phosphate undergoing auto-oxidation to generate H2O2, as previously 
mentioned (Robertson et al, 2003).  
The DCFDA assay has shown that the 100mM glucose treatment was in fact 
resulting in increased ROS production, providing supplementary evidence to the 
MTT assay results. Over 24 hour, 3 day, and 7 day treatment periods, exposure of 
HeLa cells to 100mM glucose resulted in 109.06, 123.63, and 178.95% increases 
in ROS activity respectively. As previously mentioned, high glucose 
concentrations have been proposed to result in mitochondrial dysfunction through 
increased ROS production, which this data certainly supports.  
The DCFDA assay results also lend support to the MTT assay results for the H2O2 
and sodium azide treatments. Both the 200μM H2O2 and 50μM sodium azide led 
to substantial increases in intracellular ROS levels over a 7 day time period. Over 
24 hour, 3 day, and 7 day treatment periods, exposure of HeLa cells to 200μM 
H2O2 resulted in 112.93, 135.36, and 305.56% increases in ROS activity 
respectively. Over 24 hour, 3 day, and 7 day treatment periods, exposure of HeLa 
cells to 50μM sodium azide resulted in 110.77, 134.77, and 279.13% increases in 
ROS activity respectively. Due to their previously described properties that lead 
them to interrupt mitochondrial respiration and culminate in mitochondrial 
dysfunction, the DCFDA assay provides further evidence of cellular stress 
targeted at the level of the mitochondrion by both these stressors. In saying that, 
the ROS levels of H2O2 treated HeLa cells represents a combination of residual 
H2O2 that escaped the wash protocol and ROS generated due to oxidative stress, 
so cannot be exclusively deemed to be generated by the cell’s mitochondria.  
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5 Effects of Glucose, H2O2 and Sodium Azide on HeLa 
Cell HSP Expression 
5.1 Introduction 
The previous chapters identified optimal conditions in which cells were subjected 
to treatments which resulted in mitochondria specific cell stress, as determined in 
Chapter 4. It is known that part of the cellular stress response culminates in the 
induction of HSP expression. Specifically, HSP60 induction is evidence of 
mitochondria specific stress and HSP70 induction is indicative of a general 
cellular stress (Martinus et al., 1996). On this basis, we therefore wanted to assess 
the level of HSP60 and HSP70 expression in HeLa cells upon exposure to glucose, 
H2O2, and sodium azide at sub-lethal concentrations optimised for mitochondrial 
impairment. The level of HSP60 and HSP70 expression was determined by 
western blot. 
5.2 Methods 
5.2.1 Heat Shock Control Cells 
As a means of obtaining a positive control, a heat shock treatment was also 
utilised following much of the same protocol of Martinus and colleagues from 
1996. HeLa cells were grown in a culture flask for 3 days, so as to reach the 
exponential growth stage. The media was then replaced with DMEM pre-warmed 
to 45˚C, and placed into a 45˚C incubator for 20 minutes. Following heat 
treatment, the media was again replaced, this time with DMEM pre-warmed to 
37˚C. The culture was returned to standard incubating conditions for 6 hours. 
After this time, the cells were harvested for protein extraction.  
5.2.2 Protein Extraction 
Harvested HeLa cells treated with glucose (100μM), H2O2 (200μM), sodium azide 
(50μM) and a control sample grown over 3 and 7 days, along with the heat shock 
cells, were treated with 100μL TENT buffer freshly supplemented with 1μL 
40mM PMSF. The cells were ruptured by vortexing, and were subsequently 
incubated at 4°C for 30 minutes before being spun down at 10,000rcf for 5 
minutes at 4°C to pellet cell debris. The supernatant was transferred to a new tube 
and protein concentration was estimated. Samples were stored at -20˚C. 
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5.2.3 Protein Estimation 
Protein concentration was estimated using the BCA Protein Assay kit. 200μL was 
added to 10μL of sample protein, as well as a 1:10 dilution of samples. The plate 
was then mixed briefly on a minishaker for 30 seconds before incubating at 37°C 
for 30 minutes. The plate was then read at 570nm. The concentration of each 
protein sample was determined by entering the absorbance value into the line of 
best fit equation determined by the BSA standard curve, as mentioned in Chapter 
2.3.2. 
5.2.4 Protein Separation and Transfer 
Total protein was separated on 10% polyacrylamide gels, made as described in 
Chapter 2.3.3. 20μg total protein was made up to 20μL with protein loading 
buffer. The samples were denatured in boiling water for approximately 5 minutes 
before loading into the wells. 2μL of protein ladder was run alongside the samples. 
The gel was electrophoresed at a constant 20mA as the bands ran through the 
stacking gel, and 30mA through the resolving gel. The end point was determined 
as when the loading dye ran off the gel. The protein was then transferred to a 
PVDF membrane via semi-dry transfer was 3-buffer system. The transfer cell was 
run at 15V for 35 minutes. Efficient transfer was then confirmed with Ponceau S 
staining.  
5.2.5 Western Blotting 
Membranes were blocked in 10% skim milk in TBST overnight. After six 5 
minute washes in TBST, they were incubated in primary antibody (rabbit anti-
HSP60/70/actin) diluted 1:250 in 5% skim milk in TBST overnight at 4˚C. They 
were again washed 6 x 5 minutes before being incubated in secondary antibody 
(anti-rabbit) diluted 1:1000 in 5% skim milk in TBST for 5 hours at RT on a gyro 
rocker. After another 6x5 minute washes the membrane was incubated with 
SuperSignal west substrate for 5 minutes, and then visualised. Bands were 
quantified and normalised to actin (Chapter 2.3.4).  
 
 
 83 
  
5.3 Results 
5.3.1 HSP60 
After total protein was separated on a polyacrylamide gel and transferred to a 
PVDF membrane, Ponceau S staining was used to show the standard HSP60 band 
to be at 60kDa and that protein loading was even. After western blot, a single 
band for each sample was seen and the bands appeared to be the same size as the 
standard HSP60 protein band. The bands were then quantitated using the Gel 
Quant software, and the relative expression to the control was plotted. 
HSP60 protein expression was found to be upregulated in all treatments over 3 
days. The heat shocked cells had a 2.23 fold increase in HSP60 expression, while 
the 100mM glucose, 200μM H2O2, and 50μM sodium azide had 1.61, 1.54 and 
2.12 fold increases respectively. All were significantly different to the control (p < 
0.05). 
 
 
Figure 5.1- Western blots of HSP60 and actin in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM), respectively, over 3 days. 
 
Figure 5.2- Relative HSP60 expression in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over 3 days. Bar graph showing the 
mean ± S.E.M. * = p < 0.05.  
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Additionally, HSP60 protein expression was found to be further upregulated in all 
treatments over a 7 day treatment period. The heat shocked cells had a 2.38 fold 
increase in HSP60 expression according to these membranes. The 100mM 
glucose, 200μM H2O2, and 50μM sodium azide had 2.43, 3.58 and 4.74 fold 
increases respectively, and each was significantly different from the control (p < 
0.05).  
 
 
 
Figure 5.3- Western blots of HSP60 and actin in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over 7 days.  
 
 
Figure 5.4- Relative HSP60 expression in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over 7 days. Bar graph showing the 
mean ± S.E.M. * = p < 0.05. 
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5.3.2 HSP70 
After the HSP60 western blot, the PVDF membrane was stripped of the bound 
antibodies and was again blocked. A western blot for HSP70 was then carried out, 
and a single band for each sample was seen. The bands were then quantitated 
using the Gel Quant software, and the relative expression to the control was 
plotted. 
HSP70 protein expression was also found to be upregulated in all treatments over 
3 days. The heat shocked cells had a 2.50 fold increase in HSP70 expression, 
while the 100mM glucose, 200μM H2O2, and 50μM sodium azide had 1.85, 1.71 
and 2.23 fold increases respectively. Each sample was significantly different from 
the control (p < 0.05).  
 
 
Figure 5.5- Western blots of HSP70 and actin in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over 3 days.  
 
 
Figure 5.6- Relative HSP70 expression in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over 3 days. Bar graph showing the 
mean ± S.E.M. * = p < 0.05. 
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Additionally, HSP70 protein expression was found to be further upregulated in all 
treatments over a 7 day treatment period. The heat shocked cells had a 2.50 fold 
increase in HSP70 expression. The 100mM glucose, 200μM H2O2, and 50μM 
sodium azide had 2.75, 3.98 and 5.08 fold increases respectively, and each was 
found to be significantly different from the control (p < 0.05). 
 
 
 
Figure 5.7- Western blots of HSP70 and actin in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over 7 days.  
 
 
Figure 5.8- Relative HSP70 expression in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over 7 days. Bar graph showing the 
mean ± S.E.M. * = p < 0.05. 
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5.4 Discussion 
In this section of the study, HSP60 and HSP70 protein expression was measured 
in HeLa cells treated with 100mM glucose, 200μM H2O2, and 50μM sodium azide 
for 3 and 7 days.  
It is of interest that the protein levels of both HSP60 and HSP70 continued to 
increase under all treatment conditions from 3 to 7 days of treatment. This is 
clearly shown in Figure 5.9 and Figure 5.10. As both HSP60 and HSP70 are 
upregulated under these conditions, it can be assumed that a number of stress 
responses are occurring, including a mitochondria specific response as well as a 
more general cellular response. 
.  
 
Figure 5.9- Relative HSP60 expression in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over both 3 and 7 days. Bar graph 
showing the mean ± S.E.M. * = p < 0.05. 
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Figure 5.10- Relative HSP70 expression in cells treated with heat shock, glucose 
(100mM), H2O2 (200μM), and sodium azide (50μM) over both 3 and 7 days. Bar graph 
showing the mean ± S.E.M. * = p < 0.05. 
 
As previously discussed in Chapter 1.5, HSP60 plays a critical role in the 
molecular cellular stress response targeted at the level of the mitochondrion. The 
primary role of HSPs is that of a molecular chaperone, where they act to mediate 
the folding, assembly or translocation across the intracellular membranes of other 
polypeptides; and a role in protein degradation, making up some of the essential 
components of the cytoplasmic ubiquitin-dependent degradative pathway (Burel 
et al., 1992). Additionally, when exposed to a various proteotoxic stressors, the 
expression of HSPs is induced in order to minimise cellular damage, as well as to 
stave off apoptosis, by stabilising compromised proteins. 
Due to the universal and fundamental nature of the molecular stress response 
which culminates in HSP upregulation, compiling a complete list of stressors that 
do activate it is a difficult, expensive, and time consuming task. Known stressors 
include exposure to various cytotoxins, infection, inflammation, exercise, hypoxia, 
and water deprivation (Santoro, 2000).  
The known stressor that particularly applies to this set of experiments is oxidative 
stress, as increased levels of intracellular ROS have been previously documented 
to have HSP inducing properties (Vayssier and Polla, 1998). As previously 
mentioned in Chapter 1.5, the inducible HSP component of a cell’s total HSP 
* * 
* * 
* 
* 
0
1
2
3
4
5
6
Control Glucose H2O2 Sodium Azide
Fo
ld
 C
h
an
ge
 in
 H
SP
7
0
 E
xp
re
ss
io
n
 
3 day
7 day
 89 
  
pool is regulated by HSFs, of which HSF-1 is the major regulator. In the absence 
of cellular stress, HSF-1 is inhibited due to its association with HSPs and is 
therefore maintained in an inactive state. If and when a cellular stress does occur, 
the HSPs bind to any misfolded proteins, and subsequently dissociate from HSF-1. 
This allows the HSF-1 monomers to oligomerise and form active trimers, 
regaining their DNA binding activity. The trimers undergo stress-induced serine 
phosphorylation and are translocated to the nucleus (Prahlad and Morimoto, 2008). 
Upon nuclear localisation, HSF-1 binds to the HSE situated upstream of heat 
shock responsive genes, which results in HSP gene transcription. However, the 
mechanisms for stress sensing and signalling to activate HSF-1 have not been 
fully elucidated. However, there is growing evidence in the literature that this 
mechanism is mediated by ROS, and in particular H2O2 (Ahn and Thiele, 2002).  
H2O2 has been found to induce a concentration-dependent transactivation and 
DNA-binding activity of HSF-1, although to a lesser extent than that of the 
classical heat shock treatment (Jacquier-Sarlin and Polla, 1996). Sensing of the 
oxidative stress requires two cysteine residues within the HSF-1 DNA-binding 
domain that are engaged in redox-sensitive disulfide bonds. HSF-1 derivatives in 
which either or both of these cysteine residues are mutated have been found to be 
defective in stress-inducible trimerization and DNA binding, stress-inducible 
nuclear translocation and HSP gene trans-activation, and in the protection of 
mouse cells from stress-induced apoptosis (Ahn and Thiele, 2002). In this way, 
H2O2 exerts two effects on the activation and the DNA-binding activity of HSF; 
H2O2 favours the nuclear translocation of HSF, while also altering the HSFs 
DNA-binding activity, which is achieved by oxidizing the two critical cysteine 
residues within the DNA-binding domain (Jacquier-Sarlin and Polla, 1996). 
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It would appear, based on the results from Chapters 4 and 5 and the evidence in 
the literature, that the HSP60 and HSP70 upregulation resulting from treatment of 
HeLa cells with high glucose, H2O2, and sodium azide is the result of an increase 
in intracellular ROS activity. That is to say that it appears the degree of oxidative 
stress induced by the treatment is proportional to the degree of HSP induction. 
This is shown in Figure 5.11. 
 
Figure 5.11- Relative ROS activity, HSP60 expression, and HSP70 expression in cells 
treated with glucose (100mM), H2O2 (200μM), and sodium azide (50μM) over 7 days. 
Bar graph showing the mean ± S.E.M. * = p < 0.05. 
After 7 days of treatment with 100mM glucose the intracellular ROS activity had 
increased by 178.95%, the HSP60 expression had experienced a 2.43 fold increase, 
and the HSP70 a 2.75 fold increase. As discussed in Chapter 4, hyperglycaemia 
has been reported to increase oxidative stress by increasing the rate of glycolysis 
while inhibiting oxidative phosphorylation (Crabtree, 1928). The build-up, and 
subsequent auto-oxidation, of glyceraldehyde-6-phosphate which ensues from 
increased glycolysis results in the generation of H2O2. As a result, the 
mitochondrion experiences an increase in ROS generation. As mentioned earlier 
in this chapter, activation of HSF-1, the major regulator of HSPs, is redox 
dependent. Thus, the induction of HSP60 and 70 expression may be explained by 
the increased oxidative stress that the 100mM glucose treatment resulted in. 
After 7 days of treatment with 200μM H2O2 the intracellular ROS activity had 
increased by 304.56%, the HSP60 expression had experienced a 3.48 fold increase, 
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and the HSP70 a 3.98 fold increase. While the results of the DCFDA assay from 
Chapter 4 reflects the ROS that has been truly generated from within the cell for 
the high glucose and sodium azide treatments, for the H2O2 treatment it is not so 
clear cut seeing as H2O2 is a ROS in itself.  Therefore, the ROS levels of H2O2 
treated HeLa cells, as measured by the DCFDA assay, represents a combination of 
residual H2O2 that escaped the wash protocol and ROS generated due to oxidative 
stress. As a result, the induction of HSP expression is not as pronounced as one 
may have predicted, which indicates that it is perhaps ROS generated from within 
the cell by the mitochondria as a result of the simulated oxidative that has the 
most significant effect on HSF-1 activation and therefore HSP induction. 
After 7 days of treatment with 50μM sodium azide the intracellular ROS activity 
had increased by 279.13%, the HSP60 expression had experienced a 4.74 fold 
increase, and the HSP70 a 5.08 fold increase. Unlike the other two treatments, 
sodium azide actively inhibits the mitochondrial electron transport system by 
binding irreversibly to the heme group of complex IV. Not only does this result in 
inefficient reduction of molecular oxygen by the electron transport chain resulting 
in increased ROS generation like the other two treatments, but it also prevents 
ATP generation by preventing the maintenance of the hydrogen ion gradient 
across the inner mitochondrial membrane. This may help to explain why treatment 
with sodium azide resulted in a greater induction of HSP60 and HSP70 expression. 
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6 Final Summary and Future Directions 
This study looked at several aspects of high glucose, H2O2, and sodium azide 
treatment on human HeLa cells. At low levels each treatment had a hormetic 
effect on HeLa cell growth; however at high concentrations growth was 
significantly inhibited. Additionally, high treatment concentrations resulted cell 
lysis as determined by the LDH assay. The 100mM glucose, 200μM H2O2, and 
50μM sodium azide treatments were the only treatment concentrations that did not 
result in significantly different levels of cell lysis when compared to a control 
sample. On the other hand, the 125mM glucose, 250μM H2O2, and 100μM sodium 
azide treatments were the only treatment concentrations that resulted in 
significantly increased levels of cell lysis when compared to a control sample. 
Mitochondrial dehydrogenase activity was also found to be significantly 
decreased at high treatment concentrations. Thus, the 100mM glucose, 200μM 
H2O2, and 50μM sodium azide treatments were identified as optimal conditions 
for mitochondria targeted cell stress as each of these treatments impaired cell 
growth and inhibited mitochondrial while having not significantly increasing the 
degree of cell lysis.  
The 100mM glucose, 200μM H2O2, and 50μM sodium azide treatments were then 
investigated for the intracellular ROS activity they culminated in over treatment 
periods of 24 hours, 3 and 7 days. After 7 days of treatment, the 200μM H2O2 and 
50μM sodium azide treatments resulted in approximately 3 times greater ROS 
activity, while the 100mM glucose treatment resulted in almost twice as much 
ROS.  
Finally, the effects of 100mM glucose, 200μM H2O2, and 50μM sodium azide 
treatments on HSP60 and 70 expression was also examined over 3 and 7 day time 
periods. After the 7 day treatment period, the 100mM glucose treatment had 
induced a 2.43 fold increase in HSP60 expression and a 2.75 fold increase in 
HSP70 expression, the 200μM H2O2 induced a 3.48 fold increase in HSP60 
expression and a 3.98 HSP70 expression, and finally the 50μM sodium azide 
induced a 4.74 fold increase in HSP60 expression and a 5.08 fold increase in 
HSP70 expression.  
As a result, this study has come close to achieving the development of a model to 
study HSP60 expression in human cells under conditions of mitochondrial 
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impairment. Three different treatments have been optimised to result in 
mitochondria specific cell stress, but not necrotic cytotoxicity, of human HeLa 
cells. However, these treatments also result in the induction of both HSP60 and 
HSP70 expression. This indicates that while there is a mitochondria specific stress 
response occurring, there is also a general cellular stress response taking place too. 
Therefore, the treatment protocols must still be modified to achieve a strictly 
mitochondria specific stress response. Once this has been achieved, treatments can 
be further exploited to study the downstream mechanisms and effects of HSP60, 
particularly pertaining to its extracellular expression.  
 
The results of this study agree with the literature, that increased intracellular ROS 
activity in cells with compromised mitochondria activates a HSP response. This 
has implications for T2D and obesity in particular, as increased levels of 
circulating HSP60 has been documented in individuals diagnosed with these 
metabolic diseases (Märker et al, 2012; Shamaei-Tousi et al, 2006). This study 
indicates that the hyperglycaemia and elevated oxidative stress, which are both 
associated with these diseases, are both possible stressors that lead to the observed 
increased extracellular HSP expression. This is of particular interest as HSP60 has 
been linked to the development of atherosclerosis, and patients of T2D and 
obesity are predisposed to developing CVDs. HSP60 may therefore represent the 
molecular link between the two.   
As mentioned in Chapter 5, seeing as these treatments result in the activation of 
multiple stress responses, it would be of interest to investigate if any early 
apoptotic signalling is occurring. Such developments towards a commitment to 
apoptosis could be determined in a number of ways, such as a cytochrome c assay. 
Cytochrome c is an appropriate way of measuring apoptosis as it is usually strictly 
located in the mitochondria. However, when a cell is entering apoptosis 
cytochrome c is leaked into the cytoplasm through the Bax protein channels that 
insert into the outer mitochondrial membrane upon stress detection (Guo et al, 
2002).  
It would also be of benefit to run additional long term treatments for the HSP 
western blots, say 14 and 21 days, to give a better indication of chronic exposure 
to such conditions, as is the case in metabolic conditions like T2D and obesity. 
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Along with new time periods, new treatments should also be investigated. It 
would be of particular interest to target mitochondrial impairment at different sites 
of inhibition. Such points may include mitochondrial protein synthesis, using 
azidothymadine (AZT), mitochondrial DNA replication, using ethidium bromide, 
and other components of the electron transport chain, using rotenone. Furthermore, 
it may be of interest to look at mitochondrial redox-rescue strategies aimed at 
maintaining treated cells with impaired mitochondrial capacity.   
Extracellular HSP60 has been implicated in having deleterious immunogenic 
effects, as previously discussed in Chapter 1.5. In particular, HSP60 has been 
purported to promote the CVD development in T2D and obesity. Therefore, it 
would be of interest to determine if the increased expression of HSPs 
intracellularly with treatments of 100mM glucose, 200μM H2O2, and 50μM 
sodium azide is matched with an increase of HSPs in the media. It would also be 
of interest to look at any change as to the surface expression of HSP60 with these 
treatments using confocal microscopy. There is also little known as to the 
translocation and secretory mechanisms of HSP60 which confocal microscopy 
could also be used to address. 
It would also be of benefit to see how universal the effects of these treatments are 
across various human cell lines. Due to the suspected role HSP60 plays in 
atherosclerotic development, it would be of particular interest to investigate this in 
human monocytes, such as the human acute monocytic leukaemia THP-1 cell line. 
If it is indeed a universal effect and THP-1 cells are found to upregulate HSP60 
expression in response to high glucose, H2O2, and sodium azide, an exciting 
experiment to conduct would be that of a co-culture. The experiment would 
involve co-culturing THP-1s, stressed with these various stressors, with an 
endothelial cell line, such as HUVECs, in a biochip capable of simulating the 
shear stress present in human blood vessels. By monitoring the HUVECs for the 
induction of pro-inflammatory factors, such as TNF-α, as well as atherosclerotic 
plaque formation, it can be observed whether the exposure of monocytes, which 
have been stressed to induce HSP60 expression, to HUVECs culminates in 
atherosclerotic development. If this too is found to be positive, characterising the 
receptor/s that HSP60 binds to and the signal transduction pathway that responds 
to receptor binding to illicit a pro-inflammatory response could be of immense 
importance in the development of treating and preventing the development of 
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CVDs in at risk individuals, particularly individuals diagnosed with T2D and 
obesity.  
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